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Nm23 genes which encode nucleoside diphosphate kinases (NDPKs) are 
ubiquitous metabolic enzymes, responsible for the synthesis of nonadenine nucleoside 
triphosphates from the corresponding diphosphates, with ATP as phosphoryl donor. In the 
brain, nm23/NDPK have been implicated to modulate neuronal cell proliferation, 
differentiation, and neurite outgrowth. The nm23-M2 gene is the focus of this thesis 
because this gene was found to be up-regulated during n-butyric acid induced MN9D 
differentiation through subtractive library screening and micro-array analysis. Reviews of 
relevant literature also supported its involvement in cell development and differentiation.  
Moreover, overexpression of nm23 genes induces neuritogenesis and stimulates the 
differentiation pathways in many cell lineages.  
In order to determine what role, if any, nm23-M2 gene might play in 
dopaminergic neuronal differentiation, this study made use of a catecholamine producing 
hybrid dopaminergic cell line, MN9D as an in vitro cell model system for overexpression 
and siRNA interference experimentation. The temporal expression was studied during n-
butyric acid induced MN9D differentiation by measuring the endogenous level of nm23-
M2 mRNA by semi-quantitative real-time PCR. GFP reporter system was also used to 
analyze the spatial expression pattern of nm23-M2-GFP protein in MN9D and SH-SY5Y 
cell lines using fluorescent microscopy techniques. It was demonstrated for the first time 
that overexpression of nm23-M2 itself in MN9D cell line resulted in significant increase 
in the number of cells bearing neurites and an alteration of the cell cycle, increased G1-
phase. Analysis of immunoblots revealed that this morphological differentiation was 
accompanied by an increased expression of a neuronal maturation marker, synaptosomal 
protein SNAP-25 and decreased expression of a G1 stage cell cycle marker, cyclin D1. 
The n-butyric acid-induced neurite outgrowth in MN9D cells was also abolished by 
  viii
nm23-M2 siRNA treatment although the level of SNAP-25 and cyclin D1 remained 
unaltered by siRNA interference. Therefore, it is plausible that nm23-M2 gene 1) 
regulates neurite outgrowth in dopaminergic MN9D cells acting via the modulation of 
SNAP-25 gene expression, and 2) represses transcription of positive regulators, cyclin D1 
of cell cycle, to initiate cell cycle arrest. 
These data support the hypothesis that nm23-M2 plays a role in dopaminergic 
neuronal differentiation through initiating neurite outgrowth and inducing growth arrest. 
The findings and proposed future work may eventually contribute to the understanding of 
pathways or mechanisms on the induction of dopaminergic neuron differentiation that 
could facilitate the development of gene delivery or cell replacement therapeutics for 
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Chapter 1: Introduction 
 
1.1 Prevalence of Parkinson’s Disease in Singapore 
Parkinson Disease (PD) is the 2nd most common neurodegenerative 
disorder after Alzheimer’s disease. Estimate of prevalence rates worldwide range 
from 10 to 450 per 100,000 population (Zhang and Roman, 1993). Both genetic 
and environmental agents have been implicated in PD (Tan et al. 2000; Allam et 
al. 2005). A recent study in Singapore (Tan et al. 2004) showed that PD occurs as 
commonly as in the West. 3 out of every thousand individuals, aged 50 years and 
above, will have this disease. Prevalence of PD was also investigated between 
Singapore Chinese, Malays and Indians and the environmental factors may be 
more important than racially determined genetic factors in the development of PD. 
As Singapore’s population continues to age, the number of people with PD is 
expected to rise. Due to the increasing proportion of elderly individuals, PD 
represents a growing burden on the health care system. 
 
1.2 Parkinson’s Disease 
 In 1817, British physician and geologist James Parkinson gave the first 
clear description of what is now known as PD in "An Essay on the Shaking 
Palsy”. By observing people on the streets on London, he noticed that some had 
tremors, or shaking palsy, that worsened over time. In this early stage of medical 
science, physical tests and examinations of this disease were unheard of. Dr. 
James Parkinson could not know the full range of symptoms that would eventually 
be referred as PD. Through years of dedicated research, scientists searched further 
for the causes and symptoms of PD. It is now known that PD is a 
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neurodegenerative disorder in which the most predominant neuropathological 
feature is characterized by a progressive loss of the midbrain mesencephalic 
dopaminergic neurons located in the substantia nigra pars compacta (SNpc) and 
ventral tegmental area (VTA) that provides innervation to the striatum 
(nigrostriatal system) and the cortex and limbic areas (mesocortical and 
mesolimbic system), respectively. Clinically, most PD patients show signs of the 
cardinal symptoms of bradykinesia, resting tremor, rigidity, and postural 
instability (Bergman and Deuschl, 2002; Fahn, 2003). A number of patients also 
suffer from autonomic, cognitive, and psychiatric disturbances. The pathological 
hallmarks of PD are round eosinophilic intracytoplasmic proteinaceous inclusions 
termed Lewy bodies (LBs) and dystrophic neuritis (Lewy neuritis) present in 
surviving neurons (Forno, 1996).  
  
1.3 Dopaminergic neurons 
 Dopaminergic neurons are an anatomically and functionally heterogeneous 
group of cells, localized in the diencephalons, mesencephalon and the olfactory 
bulb (Björklund & Lindvall, 1984). The most prominent dopaminergic cell group 
resides in the ventral part of mesencephalon, which contains approximately 90% 
of the total number of brain dopaminergic cells. The mesencephalic dopaminergic 
system has been subdivided into the nigrostriatal, mesolimbic and mesocortical 
system. The mesolimbic and mesocortical dopaminergic systems, which arise 
from dopaminergic cells present in the ventral tegmental area (VTA). The cells of 
the VTA in mesolimbic dopaminergic system project most prominently into the 
nucleus accumbens, olfactory tubercle but also innervate the septum, amygdale 
and hippocampus, whereas the cells in the medial VTA of the mesocortical 
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dopaminergic system project to the prefrontal, cingulated and perirhinal cortex. 
Probably the best known is the nigrostriatal system which originates in the zona 
compacta of the substantia nigra and extends its fibers into the caudate-putamen 
(dorsal striatum). The identity of early proliferating dopaminergic progenitor cells 
and development of the nigrostriatal dopaminergic neurons in the ventral 
mesencephalon floor are specified by the existence of two secreted signaling 
proteins, sonic hedgehog (Shh) (Hynes et al. 1995) and fibroblast growth factor 8 
(Fgf8) (Ye et al. 1998), derived from the floor plate of the ventral midline and the 
mid/hindbrain border, respectively. These neurons are the source of striatal 
dopamine (DA), a major neurotransmitter that is responsible for motor functions. 
The specific loss of dopaminergic neurons in the SNpc is a trait of PD and results 
in severe motor disturbances and abnormalities, while alterations in dopaminergic 
transmission from the VTA has been implicated in schizophrenia and drug 
addiction. Due to the importance of these DA neurons in human pathology, 
survival and induction of dopaminergic neurons has always been the subject of 
intense study. 
  
1.4 Therapies used in treatment of Parkinson’s disease 
While there are multiple causes of this neurodegenerative disease 
including environmental, genetic and age-associated factors, the treatments may 
be targeted at similar underlying mechanisms via neuroprotective and reparative 
intervention. Many data show that the selectively susceptible DA neurons in the 
substantia nigra of the patients that have developed Parkinson’s disease can be 
altered by protective and reparative therapies. Traditional oral drug administration 
of levadopa (L-Dopa), the precursor of DA, initially was shown to improve life 
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expectancy and relieves parkinsonian motor signs during the first six years of 
therapy (Dunnett and Bjorklund, 1999; Tan, 2001; Weiner 1982), but its 
protective effectiveness was subsequently shown to decline and long term use is 
associated with severe fluctuations in drug response (Agid et al. 1990; Curtis et al. 
1984). Pramipexole, an antiparkinsonian agent which is neuroprotective against 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced damage to the DA 
system in mice (Kitamura et al. 1997). This dopamine agonist has become an 
efficient and safe drug for the treatment of Parkinson's disease recently (Bennett 
and Piercey, 1999). However, particular caution has to be exercised in younger 
Parkinson's disease patients with a shorter disease duration regarding the 
occurrence of sudden onset of sleep (Moller and Oertel, 2005). Initial symptoms 
in PD such as oxidative stress, protein abnormalities, and cellular inclusions could 
be treated by antioxidants (Prasad et al. 1999; Shults, 2005) and trophic factors 
(Grondin and Gash, 1998). If the delay of degeneration is not sufficient, then 
immature dopamine neurons can be placed in the parkinsonian brain by 
transplantation. Such neurons can be derived from stem cell sources or even 
stimulated to repair from endogenous stem cells. Many new strategies are being 
pursued in the development of new therapies for PD. These range from the use of 
neurotrophic factors (Takayama et al. 1995), gene therapy or genetic manipulation 
to increase the volume of dopamine production by increasing the number of 
human tyrosine hydroxylase (TH) transcripts by employing viral vectors (Choi-
Lundberg et al. 1997), or transplantation of xenogeneic materials (Deacon et al. 
1997), or transplantation of human fetal tissue (Olanow et al. 1996) to deep brain 
stimulation (Diamond and Jankovic, 2005; Olanow et al. 2000). The search for 
candidate molecules that promote the regeneration and survival capacities of DA 
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neurons is a major area of investigation and hope. A better characterization of the 
developmental pathways that govern the specification, differentiation, and 
survival of these neurons will be essential in devising therapies aimed to rescue or 
replace midbrain DA neurons in Parkinson's patients. 
 
1.4.1 Neuroprotection by neurotrophic factor interventions 
 The replacement or supplementation of a DA neurotrophic factor (NTF) 
may protect or slow down the neuronal degeneration of PD. Several NTFs have 
shown trophic activity in the DA system, including brain-derived neurotrophic 
factor (BDNF) (Hyman et al. 1991), neurotrophin NT-3, NT-4/5 (Hyman et al. 
1994b, Hynes et al. 1994), basic fibroblast growth factor (bFGF) (Knusel et al. 
1990; Mayer et al. 1993; Takayama et al. 1995), transforming growth factor-β 
(TGF-β) (Poulson et al. 1994), and glial cell line-derived neurotrophic factor 
(GDNF) (Lin et al. 1993). Of relevance to the neurodegenerative processes of PD, 
pretreatment of DA neurons with BDNF protects against the neurotoxic effects of 
N-methyl-4-phenylpyridinium ion (MPP+) and 6-hydroxydopamine (6-OHDA) in 
vitro, perhaps by increasing levels of antioxidant enzyme glutathione reductase 
(Spina et al. 1992). NT-4/5 (Hynes et al. 1994), bFGF (Park and Mytilineou, 
1992), GDNF (Hou et al. 1996), and TGF-β (Krieglstein and Unsicker, 1994) also 
protect against the toxic effects of MPP+ in vitro.  
 
1.4.2 Gene transfer therapy 
 Future treatment modality for PD may also rely on using gene delivery or 
gene therapy. Recent development in aging PD models using lentiviral transfer of 
GDNF has also created hope and interest in the development of PD treatment 
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(Kordower et al. 1993). Much advancement in viral-based vectors for gene 
delivery to cells of the brain has been achieved (Bowers et al. 1997; Mandel et al. 
1998; Verma and Somia, 1997). However, future improvements must still be 
made in respect to the safety and efficiency of gene transfer to neurons. Some 
desired features of the viral vectors for gene transfer to the brains are (i) a large 
transgene capacity needed within a vector to include gene(s) of interest and its 
appropriate regulators, (ii) a high transduction efficiency needed to transfer a gene 
of interest to a population of neural cells, (iii) a good stability in transgene 
expression, (iv) that an appropriate dose of transgene product can be critical 
(Bowers et al. 1997), (v) the cell specificity of gene transfer within the central 
nervous system dependent on the cell-specific promoters (Klein et al. 1998; Song 
et al. 1997), expression of viral vector-specific receptors (Montgomery et al. 
1996), or route of axonal transport of the vector in the brain, and finally (vi) the 
lack of both toxicity and inflammatory immune response is essential for clinical 
application of viral vector-mediated gene transfer (During et al. 1994; Fraefel et 
al. 2000). Fjord-Larsen et al. 2005 recently has demonstrated Neurturin (NTN) has 
neuroprotective effects on DA neurons. However, unlike GDNF, NTN has not 
previously been applied in PD models using an in vivo gene therapy approach. 
The difficulties with lentiviral gene delivery of wild type NTN motivate the 
authors to evaluate different NTN constructs in order to optimize gene therapy 
with NTN. Currently, the enhanced secretion of active mature NTN using the 
IgSP-NTN construct was reproduced in vivo in lentiviral-transduced rat striatal 
cells and, unlike wt NTN, enabled efficient neuroprotection of lesioned nigral DA 
neurons, similar to GDNF (Fjord-Larsen et al. 2005). 
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1.4.3 Xenogeneic transplantation therapy 
 An astonishing homogeneity in neurons and glial basic cellular structure 
and function suggested that even discordant mammalian species (rodents to non-
human primates) could effectively replace local synaptic function after cell loss in 
the adult brain (Isacson et al. 1989; Hantraye et al. 1992). Such across-species cell 
transfer or xenotransplantation allows a more standardized acquisition of larger 
amount of fetal tissue as compared to human fetal tissue during abortions. Past 
transplantation studies have shown survival, function, and afferent/efferent 
connections of xenogeneic cells when transplanted into animal hosts (Galpern et 
al. 1995; Isacson et al. 1995). The immunological reaction of complement 
activation rejection and T-cell mediated responses leading to the rejection of the 
xeongrafts can be in many ways be inhibited by immune suppression. In fetal 
neural cell xenotransplantation into rodent host brains (in the absence of 
preformed anti-species specific antibodies), cyclosporine and other immune 
suppressive regimes (prednisolone and azathioprine), which are regularly used in 
humans for allogeneic kidney and heart transplantation, are usually sufficient to 
prevent massive rejection (Pedersen et al. 1995).  
 
1.4.4 Cell replacement therapy 
 One of the most promising therapies in treatment of PD is cell replacement 
therapy. It involves the transplantation of dopamine-secreting cells originated 
from human fetal ventral mesencephalon (VM) directly into the striatum. It seeks 
to replace the loss in synaptic signaling cause by the neuronal degeneration. 
Although this approach has been used successfully as a therapy for PD, one of the 
main concerns with this procedure is the significant amount of fetal tissue required 
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per transplantation. It has been previously established that, on average, it is 
necessary to obtain VM tissue from 9-12 fetuses in order to complete a bilateral 
implantation in one PD patient (Olanow et al. 1996). Another major problem is 
that the majority of the cells die during the tissue preparation (Fawcett et al. 1995) 
and first week following the graft (Barker et al. 1996; Brundin et al. 2000). 
Another problem is the use of the fetal tissue that raises ethnical concerns and 
moral issues. One solution to avoid the requirement of large number of fetuses is 
the use of neural stem cell tissue since these cells can be expanded in large 
number in culture for several months. These stem cells were isolated and purified 
from the walls of ventricles - cavities that are filled with cerebrospinal fluid within 
the brain. In this region, only about one in three hundred cells is a stem cell 
(Cassidy and Frisen, 2001).  
 
1.4.5 Deep brain stimulation therapy 
 Deep brain stimulation (DBS) has emerged rapidly as an effective therapy 
for all the cardinal features of Parkinson's disease (Breit et al. 2004). DBS 
includes an implanted brain electrode and a pacemaker-like implanted pulse 
generator. Subthalamic nucleus (STN) DBS by means of permanently implanted 
brain electrodes in appropriate patients resulted in motor improvement is 
accompanied by a significantly improved quality of life and a reduced necessity 
for medication (Israel and Hassin-Baer, 2005). Patients suffering from disabling 
motor fluctuations and dyskinesia associated with severe dopamine dysregulation 
syndrome (DDS), which is characterized by severe dopamine addiction and 
behavioral disorders such as manic psychosis, hypersexuality, pathological 
gambling, and mood swings, STN DBS greatly reduced the behavioral disorders 
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as well as completely abolished the addiction to dopaminergic treatment (Witjas et 
al. 2005). Furthermore, DBS patients may experience a significant long-term 
reduction in the cost of their pharmacologic treatment (Charles et al. 2004). 
However, mechanical failure of the DBS system is a potential complication (Alex 
Mohit et al. 2004) and signs of decreased efficacy can be seen after 12 months 
(Ghika et al. 1998). 
 
1.5 Neural stem cell and MN9D hybrid cell line 
 A neural stem cell (NSC) is defined as a single cell with the ability to (i) 
proliferate neuronal tissue, (ii) exhibit self-maintenance or renewal over the 
lifetime of the organism, (iii) give rise to a large number of clonally related 
progeny through asymmetric cell division, (iv) retain its multilineage potential 
over time, and (v) produce new cells in response to injury and disease (Zigova and 
Sanberg, 1998). The availability of a stable immortalized clonal cell lines 
expressing phenotypic characteristics of a particular subset of neurons from a 
specific area of the brain would greatly aid in the study of the neural stem cell 
differentiation into mesencephalic dopaminergic neurons. Cells generated by the 
fusion of N18TG2 cells with neurons expressing specific phenotypes of interest 
permits cloning and unlimited expansion of these monoclonal cell populations 
(Heller et al. 2000).  
 Among this cell line is a clonal catecholamine producing hybrid cell line 
designated as MN9D. It was derived from cells of mesencephalon and contains 
substantial quantities of dopamine (105 ng/mg of protein), tyrosine hydroxylase 
(TH) protein and TH mRNA. Briefly, the MN9D hybrid cells were prepared by 
polyethylene glycol-mediated fusion of cells from the embryonic rostal 
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mesencephalic tegmentum (RMT) with neuroblastoma cells (N18TG2), followed 
by isolation of monoclonal cells expressing a dopaminergic phenotype (Choi et al. 
1992).  
 The MN9D cell line shows neuronal properties including catecholamine-
specific histofluorescence, neurite formation with strong immunoreactivity to 
neurofilament proteins, and large voltage-sensitive sodium currents with the 
generation of action potentials. In contrast to the pheochromocytoma cell line 
(PC12), the dopamine content of the MN9D hybrid cell line is depleted by low 
concentration of dopamine cell-specific neurotoxin N-methyl-4-phenylpyridinium 
ion (MPP+), the active metabolite of the neurotoxin N-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) (Choi et al. 1991). Choi et al. (1992) also showed that 
the availability of MN9D cell line makes it possible to study the molecular 
mechanisms underlying trophic interactions between the central neurons. When 
MN9D cells were coaggregated with primary embryonic cells of optic tectum, a 
brain region that does not receive a dopaminergic innervation, there was a 
significant reduction in their dopamine content, tyrosine hydroxylase 
immunoreactivity, and tyrosine hydroxylase mRNA. Therefore, this shows that 
the MN9D hybrid cells are able to respond to an inhibitory factor(s) from the cell 
derived from brain areas that are not targets for dopaminergic neurons, whereas 
catecholamine-producing PC12 cells did not respond in a similar manner, 
suggesting that only the response of MN9D cells is a function of their 
mesencephalic origin (Choi et al. 1992). MN9D hybrid cell line was also reported 
to be morphological differentiated by exposure to n-butyrate (Choi et al. 1991; 
Wainwright et al. 1995). 
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1.6 Differentiation of neural stem cells (NSC) 
 The knowledge of how DA neurons can be formed would allow a 
reasonable process to be established for industrially producing a large number of 
such cells. These cells could be used for effective cell transplantation or cell 
therapy in which needed cells could be implanted under local anesthesia to brain 
regions that have lost more than 60-80% of the normal human set (500,000-
1,000,000 DA cells in the human brain, substantia nigra region) (Isacson et al. 
2001). The ability of neural stem cells to provide us with improved health and 
longevity is reliant on our ability to identify the extrinsic and intrinsic factors that 
direct the differentiation of neural stem cells to a desired lineage or phenotype. 
Induction of neural stem cells to make DA is a promising first step for cell 
replacement therapy in Parkinson’s patients. However, a number of critical 
biological and safety issues have to be resolved before clinical utility of 
embryonic stem-derived DA neurons become viable.  
 
1.6.1 Intracellular factors that cause differentiation of NSC into 
dopaminergic neurons 
 In order to study the creation of dopamine neurons from NSC to their 
highly specialized form in the adult brain, we need to start at the genetic level. 
The identification of genes controlling developmental mechanisms of ventral 
mesencephalic dopaminergic neurons can provide new insights in the etiology of 
Parkinson’s disease. A number of genes related to the development or control of 
dopaminergic identity and specialization, such as Nurr1 and sonic hedgehog 
protein, act in concert with transcription factors and downstream genetic 
activation of specific transmitter enzymes, for instance, TH and dopa-
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decarboxylase, in dopaminergic neurons (Bjorklund et al. 2000; Deacon et al. 
1998; Hynes and Rosenthal, 2000).  
 Nurr1 is an orphan nuclear receptor that belongs to the nuclear receptor 
superfamily of transcription factors that is expressed predominantly in the central 
nervous system, including developing and mature dopaminergic neurons. Nuclear 
receptors play fundamental roles in adult physiology and during development 
where they are essential for cell fate specification and differentiation of various 
cell types both within and outside of the nervous system (Kastner et al. 1995). 
During development, Nurr1 is expressed at high levels in the VM region where 
DA neurons are being generated (Zetterström et al. 1996), and Nurr1 is essential 
for the induction of phenotypic markers of ventral mid-brain dopaminergic 
neurons whose generation is specified by the floor plate-derived morphogenic 
signal sonic hedgehog. Studies have also shown that in absence of Nurr1, 
neuroepithelial cells undergo normal ventralization, differentiate into neurons, and 
adopt a specific mesencephalic phenotype that is identified by the homeodomain, 
Pitx3 (Smidt et al. 1997). However, these dopamine precursor cells are arrested in 
a developmental state described by a lack of dopamine markers and die as 
development progresses to the neonatal stage (Saucedo-Cardenas et al. 1998). 
Therefore, Nurr1 is also needed for both survival and final differentiation of VM 
late dopaminergic precursor neurons into a complete dopaminergic phenotype.  
 A previous study by Castro et al. (2001) has shown that Nurr1 can induce 
cell cycle arrest and a highly differentiated morphology in MN9D cells. However, 
the mechanism whereby Nurr1 promotes differentiation has remained unknown. 
They have also reported that retinoids could also promote the differentiation of 
MN9D cells independently of Nurr1. Retinoids (vitamin A derivatives) are known 
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to be potent inducers of cell differentiation in a variety of tissues in vivo as well as 
in many different cell lines cultured in vitro. They have demonstrated that both 
Nurr1 and retinoids promotes cell cycle arrest at the G1 phase and induce a mature 
and highly differentiated phenotype characterized by extension of long neurites 
(Castro et al. 2001). 
 Pitx3, a bicoid-related homeobox gene from the Pitx-subfamily, is a 
unique transcription factor marking the mesencephalic dopaminergic neurons at 
the exclusion of other dopaminergic neurons, are also reported to be involved in 
developmental determination of this neuronal lineage. Pitx3 expression 
completely overlapped with TH-positive cells, demonstrating that Pitx3 is 
expressed in dopaminergic neurons of mesencephalic system. Results suggested 
that Pitx3 and Nurr1 form a regulatory cascade for development of the 
mesencephalic dopaminergic neuron system in which Nurr1 may act as an 
upstream activator (Smidt et al. 1997). 
 Smidt et al. (2000) also reported that they have identified another 
transcription factor expressed in mesencephalic dopaminergic neurons, the LIM 
homeobox gene, Lmx1b, and demonstrated that, together with Pitx3, this gene 
constitutes a molecular cascade independent of Nurr1 and TH. This independent 
pathway seems to be essential for proper development of the system and may be 
linked to aspects of the mesencephalic dopaminergic system other than 
neurotransmitter identity. The data also suggested that at least two molecular 
cascades operate during the specification of the mesencephalic dopaminergic 
system, one involving Lmx1b and Pitx3 pathway that may confer mesencephalic 
dopaminergic neurons unique intrinsic properties that might be useful in directing 
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commitment of dopaminergic cells in vitro, and the other involving Nurr1, 
essential for specifying neurotransmitter phenotype.  
 Arenas (2002) had reviewed that targeted deletions of Pax2 (Favor et al. 
1996) and Pax5 (Urbanek et al. 1994), Pax 2/5 (Schwarz et al. 1997), wnt1 
(McMahon and Bradley, 1990), engrailed-1 (Wurst et al. 1994), engrailed-2 
(Hanks et al.1995) and FGF8 (Meyers et al. 1998), have all resulted in patterning 
defects in the midbrain-hindbrain region, arguing for a role of these genes in the 
establishment of midbrain and hindbrain identities. 
 
1.6.2 Extracellular factors that cause differentiation of NSC into 
dopaminergic neurons 
 Ling et al. (1998) and Potter et al. (1999) reported that pluripotent lineage-
restricted precursors derived from rat mesencephalic tissue could be expanded in 
vitro and differentiated into dopaminergic neurons using a combination of 
cytokines, growth factors, membrane fragments, and striatal culture conditioned 
media. These cells possessed numerous markers for DA neurons and were shown 
not only to survive transplantation into 6-OHDA-lesioned rats, but also produce 
significant functional recovery (Carvey et al. 2000).  
 Neurotrophic factor such as GDNF was reported to induce morphological 
differentiation of MN9D hybrid cell line (Heller et al. 1996; Lin et al. 1993). In 
another report (Rolletschek et al. 2001), neurotrophic factors, such as basic 
fibroblast growth factor (bFGF) and epidermal growth factor (EGF), in 
combination with survival-promoting factors, such as interleukin-1β, GDNF, 
neurturin, TGF-β3 and dibutyryl-cyclic AMP, significantly enhanced Nurr1 and 
TH mRNA level. They also concluded that these survival-promoting factors 
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enhance differentiation, survival and maintenance of dopaminergic neurons 
derived from embryonic stem cells in vitro. 
 
1.7 Significance of genes involved in dopaminergic neuron 
differentiation  
The elucidation of the genes and mechanisms that regulate the 
development of the dopaminergic neurons is an important goal. In addition to 
being of immense intellectual interest, the study of such genes may provide 
valuable information related to the causes and treatment of neurological and 
neurodegenerative disorder such as Parkinson’s disease. Over the past years, it has 
become clear that specific genes control dopaminergic neuron differentiation. 
Genes that are involved in the induction and regulation of such neural 
differentiation are just beginning to be discovered. However, given the enormous 
heterogeneity of genes involved and the complexity in dopaminergic neuron 
differentiation, it is not surprisingly that only a few of the required regulatory 
genes have been characterized, such as Nurr1, Pitx3, Lmx1b, etc. Thus, systematic 
searches for such genes and their differentiation pathways would be of 
significance.  
We have previously combined the technologies of suppressive subtractive 
hybridization and custom cDNA micro-array to develop a high throughput 
screening procedure to identify genes differentially expressed in association with 
dopaminergic neuron differentiation (manuscript in preparation). This subtraction-
coupled custom micro-array approach has successfully yielded a long list of 
candidate genes that were up-regulated during dopaminergic neuron 
differentiation. In this study, one of the genes in the list, namely nm23-M2 was 
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being selected for further investigation in the elucidation of its role in 
dopaminergic neuron differentiation. 
 
1.8 Literature reviews on factors that cause neurite outgrowth 
and differentiation in MN9D 
 At present, there are only 9 papers documented on investigating neurite 
outgrowth and differentiation of dopaminergic cell line using MN9D as an in vitro 
model. The originator of MN9D cell line, Heller et al. 1996, first reported on the 
application of an extrinsic neurotrophic factor, GDNF to induce morphological 
differentiation of MN9D cell line.  
 A number of putative genes were reported to induce MN9D neurite 
outgrowth such as Bcl-2 (Oh et al. 1996) and Calbindin-D28K (Choi et al. 2001). 
Overexpression of Bcl-2 in MD9D cells led to robust neurite formation without 
cessation of cell division and the neurite extension was enhanced via activation of 
c-Jun N-terminal kinase (JNK) (Eom et al. 2004, 2005). As mentioned earlier, 
both Nurr1 and retinoids promotes cell cycle arrest at the G1 phase and induce a 
mature and highly differentiated phenotype characterized by extension of long 
neurites (Castro et al. 2001). 
  Neurotransmitter receptors are known to have direct roles in the 
modulation of neuronal morphogenesis. Brief stimulation of D2, D3, D4 receptor-
expressing MN9D cells also elicited increased neurite outgrowth when treated 
with quinpirole, an agonist of D2-like receptors (Swarzenski et al. 1994). This 
stimulation which could also be mimicked by the Gi/G(o) protein activator 
mastoparandopamine in D3 receptor. This implied that D3 receptor stimulation 
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has an immediate, G-protein-mediated role in neuronal morphogenesis 
(Swarzenski et al. 1996). 
 Many studies have suggest that dysfunction of mitochondrial proton-
translocating NADH-ubiquinone oxidoreductase (complex I) is associated with 
Parkinson's disease (Wallace et al. 1992, Lestienne et al. 1990, Schapira et al. 
1990, Swerdlow et al. 1996). The single-subunit NADH dehydrogenase of 
Saccharomyces cerevisiae (Ndi1P) can be used as a replacement for complex I in 
mammalian cells. Using a recombinant adeno-associated virus vector carrying the 
NDI1 gene, the Ndi1 enzyme was expressed in MN9D (Seo et al. 2002). NDI1-
transduced cells were still capable of morphological maturation as examined by 
induction of neurite outgrowth. Hence, it is plausible that the NDI1 gene is useful 
in gene therapy in the treatment of neurodegenerative conditions caused by 
complex I inhibition. 
 
1.9 The nm23 gene family 
 The nm23 gene family includes four murine and eight human genes 
(Amrein et al. 2005). In mouse, nm23-M1, -M2, -M3, and -M4 encode for NDPKs 
A, B, C, and D, respectively. The first, referred to as nm23-M1, was isolated by 
subtractive cloning on the basis of its reduced expression in highly metastasis 
murine K-135 melanoma cell lines, as compared with their nonmetastasis 
counterparts, and has therefore been proposed as a metastasis suppressor gene 
(Steeg et al. 1988). Urano et al. 1992 first isolated the second mouse nm23 gene, 
nm23-M2 from the normal mouse liver mRNA with primers designed for the 
human nm23-H2 gene, and nm23-M2 is also intimately related with the 
suppression of metastasis in the murine body (Baba et al. 1995). Seven human 
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nm23 genes have been documented, namely nm23-H1 (Rosengard et al. 1989), 
nm23-H2 (Stahl et al. 1991), DR-nm23 (Venturelli et al. 1995), nm23-H4 (Milon 
et al. 1997), nm23-H5 (Munier et al. 1998), nm23-H6 (Tsuiki et al. 1999) and 
nm23-H7 (Seifert et al. 2005). Mehus and Lambeth identified the nm23-H8 gene 
in 1999 and its nucleotide sequences have been submitted to the GenBank 
database with the accession number AF202051 but have not yet been published 
(Amrein et al. 2005). Nm23-H1 gene has been proposed as a suppressor of 
metastatic ability in some tumor cells (Bevilacqua et al. 1989 and Fujimoto et al. 
1998). Nm23-H2 was identified as c-myc transcription factor named purine-
binding factor (PuF) (Postel et al. 1993). Several genes with highly homologous 
sequences have been characterized and shown to code for nucleoside 
diphospohate kinase (NDPK, EC 2.7.4.6) in a wide variety of organisms, 
including the prokaryote (Myxococcus xanthus) (Munoz-Dorado et al. 1990), 
lower eukaryotes (Dictyostelium discoidium) (Lacombe et al. 1990), and higher 
eukaryotes such as Drosophila (Biggs et al. 1990), Xenopus (Ouatas et al. 1997), 
and rat (Kimura et al. 1990; Shimada et al. 1993). 
   
1.9.1 Biochemical functions of nm23/NDPK proteins 
 The nm23 gene which encodes NDPK are classic ubiquitous metabolic 
enzyme that catalyzes the reversible transfer of -phosphate from nucleoside 
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 N1TP + NDPK  NDPK~P + N1DP 
 N2DP + NDPK~P  N2TP + NDPK    
 
N1TP + N2DP   N1DP + N2TP 
 
where NDP and NTP are nucleoside (or 2’-deoxynucleotide) diphosphate and 
triphosphate, respectively. The reaction involves the transient phosphorylation of 
a conserved histidine, namely histidine 118 in the human NDPK enzymes (Gilles 
et al. 1991). For example, it provides nucleoside triphosphates for nucleic acid 
synthesis, CTP for lipid synthesis, UTP for polysaccharide synthesis, and GTP for 
protein elongation. Therefore, it is an important enzyme for maintaining stable 
GTP levels through nucleotide homeostasis in various metabolic pathways such as 
protein and DNA synthesis and GTP-mediated signal transduction pathways. The 
X-ray structure of several NDPKs has been solved, showing that in eukaryotes, 
NDPKs are hexamers composed of two identical trimers (Dumas et al. 1992; 
Chiadmi et al. 1993; Williams et al 1993). Eukaryotic NDPKs have been reported 
to be catalytically active only as homo- or hetero-hexamers. In humans, the 
hexamers consist of two highly homologous subunits nm23-H1/NDPK A and 
nm23-H2/NDPK B, having an 88% amino acid sequence identity (Gilles et al. 
1991). In mouse, although the four recombinant NDP kinases can be reconstituted 
into hetero-hexamers in vitro (Lascu et al. 2000), no information is presently 
available either on the physiological effects of the relative concentration of each 
subunits in the complex formation, or on a possible involvement of these isoforms 
in vivo in the hexameric conformation of the protein.  
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 Nm23/NDPK have also been reported to exhibit a histidine protein kinase 
activity (Wagner et al. 1995; Freije et al. 1997) and a histidine-dependent protein 
phosphotransferase activity (Engel et al. 1995; Freije et al. 1997; Wagner et al. 
1997) that has been indicated as functionally involved in the metastasis 
suppressive effect of nm23-H1 (Freije et al. 1997). Specifically, the transfer of 
phosphate from recombinant nm23-H1 to aspartates or glutamates on other 
proteins correlates with the suppression of cell motility (Wagner et al. 1997). 
 Transactivating factor PuF which interacts with a nuclease hypersensitive 
element (NHE) locates upstreams from the c-myc gene. C-myc gene is a key 
regulator of cellular proliferation, embryonic differentiation and apoptosis. Nm23-
H2 recognizes the CT element/PuF site in the c-myc promoter through which it 
activates in vitro transcription (Postel et al. 1993) independently of NDPK 
catalytic activity (Postel and Ferrone, 1994). Moreover, it has been shown that 
nm23-H2 exhibits a poor binding activity to double-stranded oligonucleotides 
while preferentially binds single-stranded polypyrimindine-rich sequences 
(Hildebrandt et al. 1995; Agou et al. 1999) and it has been suggested that it 
regulates gene expression by altering promoter DNA structure (Postel, 1988). 
Furthermore, the murine nm23-M2 transactivates the c-myc gene and controls the 
cell cycle, S-phase, indirectly via a cellular cofactor in the murine cell line (Lee et 
al. 1997) and nm23-M2 activates endogenous c-myc expression both at 
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1.9.2 Cellular studies support a role for nm23/NDPK in signal 
transduction 
Increasing evidence indicates that the nm23 genes, initially documented as 
suppressors of metastasis progression, are involved in normal development and 
differentiation. Several reports suggest that, in addition to their basic enzymatic 
activity and probably independently of their catalytic site, NDPK isoforms are 
involved in other cellular functions, such as cell growth and differentiation, 
embryonic development, tumor progression, metastasis, and apoptosis (Otero 
2000; Hartsough and Steeg 2000; Kimura et al. 2000; Lacombe et al. 2000; Postel 
et al. 2000). There are many reports that document the involvement of 
nm23/NDPK in the responsiveness of cells to extracellular stimuli. Melanoma and 
brest carcinoma cells over-expressing nm23-H1 display a reduced response to the 
cytokine TGF-β1 (Leone et al. 1991, 1993) and their motility in response to 
serum, PDGF, and IGF-1 is markedly inhibited (Kantor et al. 1993; MacDonald et 
al. 1996; Russell et al. 1998). However, there are also inconsistent observations on 
the effect of nm23/NDPK on NGF signaling in PC12 cells: in one case, 
overexpression of nm23-H1 promoted NGF-induced differentiation (Gervasi et al. 
1996), while in another, it caused cells to differentiate in the absence of NGF 
(Ishijima et al. 1999). Evidently, nm23/NDKP modulate cellular signal 
transduction networks. However, the results do not follow an obviously apparent 
pattern, to date, there is still no unifying hypothesis for the role of nm23/NDPK in 
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1.9.3 Nm23/NDPK homologues in fruit fly development and 
differentiation 
The existence of multiple nm23/NDPK proteins raises the question 
whether they carry out redundant NDPK activity or, instead, perform specialized 
functions, not necessarily related to nucleoside phosphorylation, and probably 
depending on different cellular contexts. The involvement of the nm23 genes in 
normal development and differentiation is supported by several observations. The 
NDPK exhibit an approximate 75% homology with the Drosophila melanogaster 
nm23 homologue, abnormal wing discs (awd) protein (Rosengard et al. 1989) 
which also displays NDPK activity and is required for proper differentiation of 
tissues of epithelial origins. Null mutations or reduced expression of the gene 
allows normal embryonic development until metamorphosis but cause widespread 
abnormalities at the onset of tissue differentiation. The altered larvae development 
is characterized by abnormal tissue morphology, aberrant differentiation, and 
eventual necrosis of the imaginal discs, brain and proventriculus (Dearolf et al. 
1988). Normal development and differentiation are restored by transfecting the 
mutant awd germline with the wild-type awd gene (Timmons et al. 1993). The 
killer of prune (k-pn) mutation of the awd gene that changes proline 97 to serine in 
the awd protein has no effects by itself but is lethal in the genetic context of the 
prune (pn) eye color mutation (Biggs et al. 1988). Interestingly, it has been shown 
that the k-pn mutation, without coordinate expression of pn, suppresses the tum-1 
hematopoietic oncogene of Drosophila (Zinyk et al. 1993). The mechanisms 
underlying the developmental abnormalities due to awd mutations and the lethal 
interaction between pn and k-pn are still unclear (Timmons and Shearn, 1997). 
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1.9.4 Nm23/NDPK in hematopoietic differentiation   
 The relation of Nm23 genes expression to hematopoietic differentiation 
has also been investigated in several studies (Yamashiro et al. 1994). It has been 
reported that intracellular nm23-H1 expression levels decrease during in vitro 
induced differentiation of megakaryoblastic MEG-01 and promyelotic HL-60 
leukemia cell lines (Zhu et al. 2001). On the contrary, during differentiation of 
human K562 erythroleukemia cells, nm23-H1 expression levels increase. 
Furthermore, nm23-H1 cDNA-transfected K562 cells are better induced to 
synthesize hemoglobin (Yamashiro et al. 1994). The authors concluded that nm23-
H1 might contribute to the maintenance of the immature phenotype in some 
leukemia cells, whereas it might play a role in the differentiation of 
erythroleukemia cells. The presence of NDPK in human plasma and down-
regulation of nm23 expression (H1, H2 and H3) was also observed during 
maturation of CD34+ progenitor cells (Willems et al 1998; Venturelli et al. 1995), 
and nm23-H1 and nm23-H2 were strongly up-regulated after activation of 
peripheral blood lymphocytes (Keim et al. 1992). The partial amino acid sequence 
determined from cyanogens bromide fragments of the differentiation inhibiting 
factor (I-factor), purified from the conditioned medium of the differentiation-
resistant mouse myeloid leukemia M1 cell line, has shown identity with nm23-M2 
(Okabe-kado et al. 1995a), and the differentiation inhibitory activity of the 
nm23/NDPK protein is independent of its enzyme activity and requires the 
presence of N-terminal peptides (Okabe-kado et al. 1995a, 1995b). The expression 
of nm23-H1 and nm23-H2 in the majority of cells of hematopoietic origin 
suggests that, during hematopoiesis, the nm23 genes regulate different stages of 
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the differentiation process, depending on the specific cellular lineage (Okabe-kado 
et al. 2002). 
   
1.9.5 Nm23/NDPK in mammalian neuronal cell development and 
differentiation 
The positive role of nm23/NDPK during development and differentiation 
of cells and tissues has been frequently described in the literature. The high level 
of NDPK expression at the mRNA and protein levels was demonstrated in 
postmitotic rat tissues, such as heart and brain (Kimura et al. 1990; Shimada et al. 
1993). In situ hybridization and reverse transcriptase-polymerase chain reaction 
analysis demonstrated high levels of nm23-M1, -M2, and -M3 mRNA expression 
in peripheral nervous tissue and showed the differential expression of nm23 genes 
in adult mouse root ganglia (Barraud et al. 2002). Considering that the specific 
activity of NDPK in brain was higher (0.15 U/mg protein) than in other tissues 
(Mourad et al. 1966) and its expression was accumulating preferentially in the 
nervous system during the early embryonic development (Lakso et al. 1992), 
NDPK could play a pivotal role in brain functions to modulate neuronal cell 
proliferation, differentiation, and neurite outgrowth.  
The pattern of nm23 expression in tissue development has been studied by 
different approaches during embryogenesis and organogenesis. Previous 
immunohistochemical studies aiming to provide a detailed analysis of nm23 
expression patterns during mouse embryonic development have often been 
hindered by the use of antibodies unable to discriminate between the isoforms 
(Lakso et al. 1992). Subsequently, a few studies involving the use of specific 
mRNA probes have revealed the nervous expression of mRNA encoding the 
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NDPK A isoform in Xenopus (Ouatas et al. 1998), rat (Shimada et al. 1993) and 
mouse (Gervasi et al. 1998; Dabernat et al. 1999; Masse et al. 2002). In all 
organisms studied, the NDPK B isoform is expressed in most tissues. In a recent 
paper (Amrein et al . 2005), differential expression of mRNAs encoding NDPK A, 
B, C and  D isoforms at different stages of mouse development were analyzed by 
in situ hybridization on whole-mount embryos and cryostat sections. Their 
expression in adult and embryonic central and peripheral nervous system suggests 
that nm23 gene products participate in neuronal functions.  
The association of NDP kinase with microtubule protein has been 
observed in mammalian cell system (Nickerson and Wells, 1984; Lombardi et al., 
1995). An increase in the expression of nm23-M1 protein and a pattern of 
coimmunoprecipitation of nm23-M1 protein (NDP kinase alpha) and -tubulin has 
been detected under differentiation conditions, and that the number of nm23-M1/ -
tubulin complexes increased during the differentiation process of murine 
myogenic cells. All these suggested a participation of nm23 in microtubule 
assembly during differentiation (Lombardi et al. 1995). In brain, nm23/NDPK has 
been reported to be co-localized with microtubules and suggested to influence 
neurite outgrowth by altering microtubule dynamics (Huitorel et al. 1984).  
 The overexpression of nm23/NDPK could rapidly induce neurite 
outgrowth with the increased expression of neurofilament and microtubule 
proteins (Gervasi et al. 1996; Ishijima et al. 1999), brain nm23/NDKP has an 
ability to drive neuritogenesis by influencing the expression of cytoskeleton 
proteins and its deterioration could result in the defect of neuronal processes such 
as neurite outgrowth and axonal sprouting. The protective effect of NDPKs 
against oxidative stress induced cell death in BAF3 cells was also documented in 
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Arnaud-Dabernat et al. 2004. This also coincides with the report in Arabidopsis 
thaliana, the orthologous NDPK2 gene was shown to induce plant tolerance 
against several environmental stresses such as cold, salt and H2O2 by decreasing 
the level of reactive oxygen species (ROS) (Moon et al. 2003). Interestingly, the 
role of nm23/NDPK in neurodegenerative diseases was investigated in Kim et al. 
2002 and Nm23-H1/NDPK-A protein level was shown to be significantly 
decreased in brain regions (frontal, occipital, and parietal cortices) of both 
Alzheimer’s disease and Down syndrome. They proposed that oxidative 
modification of NDPK could lead to the decreased activity of NDPK and 
subsequently, influence several neuronal functions in neurodegenerative diseases 
as multifunctional enzyme through several mechanisms. 
 
1.9.6 Role of nm23/NDPK in neuroblastoma differentiation 
DR-nm23 (nm23-H3) was well studied during neuroblastoma cells 
differentiation in many papers (Amendola et al. 1997, 2001; Martinez et al. 1997). 
DR-nm23 expression increased after retinoic acid induction of differentiation in 
human cell lines SK-N-SH and LAN-5. Overexpression of DR-nm23 promotes 
differentiation of human neuroblastoma cells towards neuronal and schwannocitic 
phenotype. The cells exhibited marked decrease in proliferation, increased 
differentiation related proteins such as vimentin and collagen type IV, modulation 
of integrin expression, and underwent growth arrest, which were relevant to 
differentiation. Overexpression of DR-nm23 in the murine neuroblastoma cell line 
N1E-115 also showed neurite outgrowth and a striking enhancement of beta1 
integrin expression, while mutations in the catalytic domain and in the serine 61 
phosphorylation site, possibly required for protein-protein interactions, impair the 
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ability of DR-nm23 to induce neural differentiation (Negroni et al. 2000). 
Overexpression of wild type nm23-H1 proteins in IMR-32 human neuroblastoma 
cells also stimulated spontaneous neurite outgrowth and enhanced differentiation 
in response to serum starvation and retinoic acid (Backer et al. 2000). 
 
1.10 Objective of this study 
 In order to determine what role, if any, nm23-M2 gene might play in 
dopaminergic neuronal differentiation, this study makes use of a catecholamine 
producing hybrid dopaminergic cell line, MN9D as an in vitro cell model system. 
Nm23-M2 gene was selected based on the previous findings that this gene was 
found to be up-regulated during n-butyric acid induced MN9D differentiation and 
that various relevant literature reviews also supported the notion of nm23/NDPK 
being involved in development and differentiation, moreover, overexpression of 
nm23 genes induces neuritogenesis and stimulates the differentiation pathways in 
many cell lineage. The findings of this present study may serve as a fundamental 
knowledge of how nm23-M2 gene may be involved in dopaminergic neuron 
differentiation and ultimately aid in the development of gene therapy in treating 
neurodegenerative disorders such as PD. 
  The cloning, temporal and spatial pattern of gene expression, cellular 
localization of nm23-M2 will be explored in details. Both hypothesizes of: 1) 
overexpression of nm23-M2 gene will cause MN9D cells to differentiate, inducing 
neuritogenesis and cell cycle arrest, and 2) siRNA interference of nm23-M2 gene 
will abolish neurite outgrowth of MN9D cells in differentiation conditions, were 
tested in this study. The role of nm23-M2 in dopaminergic neuronal differentiation 
would thus be elucidated by overexpression and siRNA interference studies. 
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Laboratory techniques such as molecular cloning, cell culture and transfection, 
real-time PCR, western blot analysis and flow cytometry analysis were employed 
in this study. Cell cycle analysis was performed to look at events of cell cycle 
arrest, which is a characteristic of terminal differentiation. The alteration in 
protein levels of a maturation marker, synaptosomal associated protein, SNAP-25, 
and a key cell cycle regulatory gene, cyclin D1, was monitored after each 
overexpression and RNA interference studies to investigate dopaminergic cell 
maturation and differentiation.  
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Chapter 2: Materials and methods 
 
2.1 Routine cell culture of MN9D and SH-SY5Y cell lines 
The MN9D cell is a mouse dopaminergic neuronal cell line derived from 
the fusion of rostral mesencephalic neurons from embryonic C57BL/6J mice with 
N18TG2 neuroblastoma cells (Choi et al. 1991). MN9D was deemed suitable in 
this study because it is dopaminergic and neuronal in nature – a fundamental 
feature for cell lines used as PD models. In addition, it is of mesencephalic origin 
– a feature absent in other cell models used currently. SH-SY5Y is a human 
neuroblastoma cell line established from a highly malignant tumour. The cells 
have retained a capacity to differentiate in vitro in response to low concentrations 
of the phorbolester 12-O-tetradecanoylphorbol-13-acetate (TPA) in the presence 
of serum or defined growth factors. Differentiated cells are characterized by 
neurite formation and upregulation of neuronal marker genes. The MN9D cells 
were from Dr J. Chen of the University of Pittsburgh, used with permission from 
Dr A. Heller of the University of Chicago and SH-SY5Y cells were obtained with 
courtesy from Dr. K. L. Lim (National Neuroscience Institute, Singapore). 
 Both MN9D and SH-SY5Y cells were routinely cultured in Primaria-
coated petri dishes (BD Bioscience, USA) or 100mm x 20mm polystyrene-treated 
Corning plate (Corning, USA) in Dulbecco’s MEM  (DMEM) (NUMI, Singapore) 
containing 10% fetal bovine serum (Hyclone, USA) and 1% v/v penicillin-
streptomycin (Sigma, USA). Some MN9D hybrid cells were differentiated by 
addition of 1mM n-butyric acid (Sigma, USA) to DMEM culture medium. All cell 
lines were maintained in a CO2 incubator (Binder, Germany) at 37oC, 5% carbon 
dioxide / 95% room air. The cell medium was changed every alternate day. When 
the cells were about 80-90% confluence, the medium was removed and the cells 
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were washed with 1X phosphate buffer saline (PBS) (NUMI, Singapore). The 
cells were then dislodged from the bottom of the petri dish with 1X Trypsin-
EDTA (Sigma, USA). Fresh DMEM culture medium was added to inactivate 
Trypsin-EDTA followed by dilution and distribution of the cells equally into new 
culture plates to grow. 
 
2.2 Cloning of full length nm23-M2 gene 
2.2.1 Total RNA isolation 
Cells were grown to about 80-90% confluence prior to total RNA 
isolation. Approximately 107 cells were used for each RNA isolation batch. Total 
RNA was isolated using RNeasy Mini Kit (Qiagen, USA). The RNeasy mini 
protocol for isolation of total RNA from animal cells can be obtained in RNeasy 
Mini Handbook, Third Edition (June 2001, page 31-35). The cells were disrupted 
by addition of 600µl of Buffer RLT and homogenized by passing the lysate at 
least 5 times through a 20-gauge needle fitted to an RNase-free syringe. A volume 
of 600µl 70% ethanol was mixed well with the homogenized lysate by pipetting. 
The sample was then applied onto an RNeasy mini column placed in a 2ml 
collection tube. The column was then centrifuged for 15 sec at more than 8000 x 
g. The flow-through was then discarded. A volume of 700µl Buffer RW1 was 
added to the RNeasy column and centrifuged for 15 sec at more than 8,000 x g to 
wash the column. The flow-through was again discarded. The column was then 
transferred into a new 2ml collection tube, in addition, 500µl of Buffer RPE was 
applied to the column and centrifuged for 15 sec at more than 8,000 x g. The flow-
through was then discarded. Another 500µl of Buffer RPE was added to the 
column and centrifuged for 2 min at more than 8,000 x g. The flow-through was 
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again discarded and the column was transferred into a new 1.5ml collection tube. 
A volume of 30µl RNase-free water was passed through the RNeasy silica-gel 
membrane to elute the total RNA. The column was centrifuged for 1 min at more 
than 8,000 x g. This process was repeated with another 10µl of RNase-free water 
to obtain a higher total RNA concentration. The eluted total RNA was then 
ethanol-precipitated by adding 180µl of absolute ethanol and 6µl of 3M sodium 
acetate. The samples were placed in -80oC freezer for at least 1 hour and 
centrifuged at 14,000 x g, 4oC for 30 min. The supernatant was then discarded by 
pipetting. The pellet was washed with 200µl of 70% ethanol and centrifuged for 5 
min at 4oC, 14,000 x g. The supernatant was then discarded and the pellet was air-
dried. The pellet was re-dissolved in 10µl of RNase-free water and stored in -80oC 
freezer for later use. The integrity of the total RNA can be determined by running 
a 1% agarose gel electrophoresis to see if there is any degradation of total RNA. 
The total RNA concentrations were then measured by using mass 
spectrophotometer. The total RNA was diluted with RNase-free water, placed into 
a 100µl quartz microcuvette and the absorbency at 260nm and 280nm 
wavelengths were recorded. The following formula was used to calculate the 
concentration of the total RNA: 
[RNA] = (0.04µg/µl) (A260) (Dilution factor) 
The purity of the total RNA can be estimated by the ratio of the absorbency at 260 
nm wavelength over the absorbency at 280nm wavelength.  
The total RNA yield can be calculated by multiplying the concentration by the 
volume of the total RNA sample in milliliters. 
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2.2.2 Reverse Transcriptase-PCR (RT-PCR) of full length nm23-
M2 gene 
First-strand cDNAs were synthesized from the total RNA isolated and 
polymerase chain reaction (PCR) amplification of full length mouse nm23-M2 
cDNA was carried out using Access RT-PCR System (Promega, USA). The PCR 
amplification was carried out with 1 set of specific primers (NdpkB-Forward: 5’-
ATG GCC AAC CTC GAG CGT-3’ and NdpkB-Reverse: 5’-CTA CTC GTA 
CAC CCA GTC-3’) to generate full length nm23-M2 cDNA insert.  
 
2.2.3 Gel extraction and DNA purification of nm23-M2 
The PCR product of full length nm23-M2 cDNA was subjected to DNA 
agarose electrophoresis to check on the molecular size of the cDNA insert. The 
full length nm23-M2 DNA fragment from the agarose gel was excised with a 
clean scalpel and was purified using QIAquick Gel Extraction Kit (Qiagen, USA). 
The gel slice was weighed and 3 volumes of Buffer QG was added to 1 volume of 
gel (100mg ~ 100μl). The gel slice was incubated at 50oC for 10 min while 
vortexing the tube every 2-3 min to help in dissolving the gel. Isopropanol of 1 
volume was added and the sample was applied to the QIAquick column, and 
centrifuged for 1 min. The flow-through was discarded while 500μl of Buffer QG 
was then added and centrifuged for 1 min. The flow-through was discarded while 
750μl of Buffer PE was added to wash the column. The sample was centrifuged 
for 1 min and the flow-through was then discarded. The column was then 
centrifuged again for an additional of 1 min to remove the residual ethanol. The 
column was placed into a clean 1.5ml microcentrifuge tube and 40μl of sterile 
water was used to elute the purified DNA. 
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2.2.4 Cloning of full length nm23-M2 coding sequence into 
pGEM-T EasyTM plasmid vector 
The amplified full length nm23-M2 cDNA were subsequently sub-cloned 
into the vector by using pGEM-T Easy vector system I kit (Promega, USA) and 
the recombinant plasmid was termed as pGEM-T Easy_mNm23-M2. DNA 
ligation reaction was carried out typically in 10ul of volume, containing 5μl of 2X 
ligation buffer, 0.5μl of vector DNA, 3μl of insert DNA generated by Taq DNA 
polymerase and 1μl of T4 DNA ligase and topped up with PCR water to a final 
volume of 10μl. The ligation mixture was incubated at 4oC for about 16 hr before 
transformation. The pGEM-T Easy vector map is shown in figure 2.1. 
Alternatively, thermostable DNA polymerases with proofreading activity, 
such as Pfu DNA polymerase and Tfl DNA polymerase generate blunt-ended 
fragments during PCR amplification. Nevertheless, these PCR fragments can be 
modified using the A-tailing procedure before ligating them into the pGEM-T 
easy vectors. Using this TA cloning method, only one insert will be ligated into 
the vector as compared to multiple insertions that can occur with blunt-ended 
cloning. In addition, there is on need to de-phosphorylate the vector with TA 
cloning. Briefly, 1-7μl of purified PCR fragment was mixed with 1μl Taq DNA 
polymerase 10X reaction buffer with MgCl2, 5 units of Taq DNA polymerase and 
dATP was added to a final concentration of 0.2mM. The reaction mixture was 
topped with deionized water to a final reaction volume of 10μl and then incubated 
at 700C for 15-30 min. The modified PCR fragment can then be ligated directly 
into pGEM-T easy vector using standard protocol as above. 
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2.2.5 Transformation of recombinant plasmids into bacterial 
competent cells 
2.2.5.1 Preparation of bacterial competent cells 
For the preparation of bacteria competent cells, 100ml of LB broth was 
incubated with a 5ml of Escherichia coli (E. coli) strain DH5α (Invitrogen, USA) 
at 370C with 2,700 x g shaking overnight. In the following morning, 1ml of the 
culture was spiked into 200ml of fresh LB medium and subjected to shaking at 
2,700 x g at 370C until OD590 reached around 0.4. The culture was chilled on ice 
for 15 min and transferred to pre-chilled sterile 50ml Falcon 2070 tubes. Cells 
were pelleted by centrifugation at 3,000 x g at 40C for 5 min. The LB medium was 
decanted off and the tubes left standing upside-down on a pad of C-Fold towels 
for 1 min. The cell pellet was re-suspended in 0.1M CaCl2 and put in ice for 45 
min. The cells were then pelleted by centrifugation 3,000 x g at 40C for 8 min. 
The supernatant was discarded and the cell pellets were re-suspended in 2ml of 
ice-cold 0.1M CaCl2 for each 50ml of original culture. At this point, the cells were 
either use directly for transformation or aliquoted into 1.5ml microcentrifuge 
tubes After 20 min incubation on ice, the competent cells were stored at –800C 
freezer for several months. 
 
2.2.5.2 Transformation 
A volume of 5μl of ligation reaction was mixed with 100μl of E. coli 
DH5α competent cells as prepared in section 2.2.4.1. The mixture was incubated 
on ice for 20 min and then heated at 370C for 5 min. The tube was cooled 
immediately on ice for 2 min and mixed with 400μl of LB (Luria-Bertani) broth 
(OXOID, UK) without antibiotics. After incubating it at 370C for 1 hr with 
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shaking at 2700 x g, the transformation mixture were centrifuged at 1600 x g for 1 
min and one-tenth of the mixture was aliquoted and was spread onto fresh LB agar 
plates by inoculating loops for colony selection. The LB plates were supplemented 
with X-gal (Bio-Rad, USA) and IPTG (Bio-Rad, USA) in the presence of 20μg/ml 
ampicillin (Sigma, USA). After an overnight incubation at 370C, colonies of 
transformed cells were selected according to their antibiotic resistance and lac- 
phenotype. White bacterial colonies were chosen, from each of which bacteria 
cells were picked up via a sterile toothpick and were subjected to colony screening 
for positive clones. Individual selected bacteria cells were also streaked onto a 
master LB agar plate and stored at 40C for later use. The bacteria cells on 
individual toothpick were also inoculated onto LB medium supplemented with 
20μg/ml ampicillin with incubation overnight at 370C for DNA plasmid isolation.  
 
2.2.6 Colony PCR screening for positive clones  
 Using colony PCR screening method, the following PCR reaction mixture 
was prepared: 
Reagents Volume (μl) 
10 mM dNTPs 0.4 
10X PCR reaction buffer 2.0 
MgCl2 (25 mM) 1.2 
T7 primer (20 pmol/μl) 0.2 
SP6 primer (20 pmol/μl) 0.2 
Taq polymerase 0.2 
Deionized water 15.8 
Total volume 20.0 
 
 White bacterial colonies in the culture plates were picked and individually 
mixed with the PCR reaction mixture. The following conditions were set for the 
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PCR reaction in a Peltier-Effect Cycling PTC-1000 Programmable Thermal 
Controller (MJ Research, USA): 
 Stage 1: Initial denaturation: 94oC for 2 minutes in 1 cycle. 
 Stage 2: Step 1, denaturation: 94oC for 30 seconds. 
   Step 2, Annealing: 55oC for 30 seconds. 
   Step 3, Elongation: 72oC for 1 minute. 
 Stage 2 was carried out for 40 cycles. 
 Stage 3: Final elongation: 72oC for 7 minutes. 
Colonies which contained the inserts were identified by agarose gel 
electrophoresis and were prepared for sequencing as described in section 2.2.6 – 
2.2.8. The positive clones were identified as those that contained the full length 
sequence of nm23-M2 cDNA. 
 
2.2.7  Plasmid DNA isolation from positive clones 
Small-scale isolation of plasmid DNA from positive clones was carried out 
using Qiagen Mini-prep Kit (Qiagen, Germany). It involved alkaline lyses 
followed by binding of plasmid DNA to a silica-based resin. DNA was eluted in 
low salt buffer or water. Up to 10μg of high copy number plasmid DNA can be 
isolated from 3ml of overnight bacteria culture in LB medium.  
Firstly, the bacteria in LB liquid medium with appropriate antibiotics were 
harvested by centrifugation for 5 min at 10,000 x g using the 5417C centrifuge 
(Eppendorf, Germany). The bacterial pellet was then re-suspended in 250μl of 
Cell Re-suspension Solution P1 (10mg/ml RNAse A; 10mM EDTA; 25mM Tris-
HCl, pH 7.5). 250μl of Cell Lysis Solution P2 (0.2M NaOH; 1% SDS) was added 
to the bacterial suspension and mixed by gently inverting the tubes for 4-6 times. 
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The mixture was neutralized by adding 350μl of Neutralization Buffer N3 (1.32M 
KOAc, pH 4.8). After being centrifuged in a micro-centrifuge tube at 10,000 x g 
for 10 min, the supernatant was applied into the QIAprep spin column with a 
purification resin and a fresh 2ml collection tube. The resin/DNA mix was washed 
with 750μl of Column Wash Buffer PE by centrifugation for 1 min and the flow-
through was discarded. Residual wash buffer was completely drained by spinning 
down into the collection tube at 10,000 x g for another 1 minute. The mini-column 
was then transferred to a new microcentrifuge tube and eluted with 40μl of PCR 
water. After 1 min incubation at room temperature, plasmid DNA was eluted from 
the column by centrifugation at 10,000 x g for 1 min. 
 
2.2.8 Cloning of full length nm23-M2 coding sequence into 
mammalian pcDNA3.1-GFP and pcDNA 3.1-MYC plasmid 
vector 
 The eukaryotic expression vector pcDNA3.1 (plasmid map shown in 
figure 2.2) tagged with c-Myc or GFP were obtained with courtesy from Dr. 
Arenas E. (Karolinska Institute, Sweden).  Expression plasmid encoding a GFP 
epitope-tagged version of the mouse nm23-M2 protein termed as pcDNA3.1(-)_fl 
nm23-M2_GFP was constructed as follows: PCR amplification of the full length 
Nm23-M2 gene was carried out using pGEM-TEasy_mNm23-M2 plasmid 
described above as a template with the following set of specific primers 
(NdpkB(XbaI+KS)-Forward: 5’-GGG CCC TCT AGA ACC ATG GCC AAC 
CTC GAG CGT A-3’ and NdpkB(Stop+EcoRI)-Reverse: 5’-GTG GTG GAA 
TTC CTC GTA CAC CCA GTC ATG-3’. The amplified DNA product was then 
digested with the restriction enzymes XbaI and EcoRI and ligated into the 
Chapter 2: Materials and Methods 
 
 40
pcDNA3.1(-)_GFP vector. For expression plasmid encoding a c-Myc epitope-
tagged version of the mouse nm23-M2 protein termed as pcDNA3.1(-)_fl nm23-
M2_MYC, the amplified DNA product was also digested with the restriction 
enzymes XbaI and EcoRI and ligated into the pcDNA3.1(-)_MYC vector. 
 
2.2.9 Cycle sequencing  
ABI PRISM® BigDyeTM Terminator v3.0 Ready Reaction Cycle 
Sequencing Kit 
(Applied Biosystems, USA) was used for the sequencing reactions and the 
following reaction mixtures were prepared: 
 
Reagents Volume (μl) 
Terminator Ready Reaction Mix  8.0 
T7 Primer (2 pmol/μl) 1.6 
DNA Template 8.0 
Deionized water 2.4 
Total volume 20.0 
 
 The following conditions were set for the PCR reaction in a Peltier-Effect 
Cycling PTC-1000 Programmable Thermal Controller (MJ Research, USA): 
Stage 1: Rapid thermal ramp to 96oC, 
Stage 2: Step 1: 96oC for 10 sec, 
  Step 2: Rapid thermal ramp to 50oC, 
  Step 3: 50oC for 5 sec, 
  Step 4: Rapid thermal ramp to 60oC, 
  Step 5: 60oC for 4 min, 
  Repeat the following for 25 cycles. 
Stage 3: Rapid thermal ramp to 4oC and hold until ready to purify. 
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2.2.10 Ethanol/sodium acetate precipitation for DNA purification 
 In order to precipitate in microcentrifuge tubes, the following mixture 
were prepared and combined to each sample: 
• 3.0μl of 3M sodium acetate (NaOAc), pH 4.6 
• 62.5μl of non-denatured 95% ethanol (EtOH) 
• 14.5μl of deionized water 
 This 80μl of ethanol/sodium acetate solution was added to 20μl of reaction 
mixture and vortexed briefly. The tubes were then incubated at room temperature 
for 15 min to precipitate the extension products. The tubes were spun in a 
microcentrifuge for 20 min at maximum speed. Followed by, aspirating and 
discarding of the supernatants with a separate pipette tip for each sample. 70% 
ethanol of 500μl was added to the tubes and mixed briefly. The tubes were then 
centrifuged again for 5 min at maximum speed. The supernatants were then 
discarded carefully and the samples were air-dried for 10-15 min.  
 
2.2.11 Capillary electrophoresis sequencing on ABI PRISM 3100 
Genetic Analyzer 
 Each sample pellet was re-suspended in 10μl of deionized high-dye 
formamide and vortexed thoroughly. The samples were denatured by heating at 
95oC for 2 min followed by chilling on ice for another 2 min. The samples were 
then loaded into the ABI PRISM® 3100 Genetic Analyzer (Applied Biosystems, 
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2.2.12 DNA gel electrophoresis 
 PCR products were analyzed by gel electrophoresis. The DNA samples 
were first mixed with 1X loading dye (6X Blue/Orange Loading Dye, Promega, 
USA). They were then loaded into the wells of 1.0% agarose (Promega, USA) gel 
in 1X TAE buffer (0.04M Tris-acetate, 0.01M EDTA, pH 8.0) with 0.4μg/ml 
ethidium bromide (Boehringer Mannheim, GmbH, Germany). A 100bp or 1kb 
DNA ladder (Promega, USA) was loaded into the wells for verifying the 
molecular size of the DNA fragments. Electrophoresis was normally carried out at 
a constant voltage of 90-100 volts in 1×TAE buffer, until the bromophenol blue 
front had migrated two-third of the length of the gel. The DNA samples were 
visualized in ultra-violet light at 254nm using BioDoc-It System UV 
transilluminator (Ultra-Violet Products, UVP, USA) and documented onto thermal 
paper by digital thermal printer (Mitsubishi, 115V, UVP, USA). 
2.3 Construction of cDNAs for Real-time PCR 
RNA was isolated using the RNAeasy Mini kit (Qiagen, USA) as 
described in section 2.2.1. To remove any contamination of genomic DNA, 1μl of 
DNase (1 unit/μl) was added to 1μg of RNA and topped up with deionized water 
to a final volume of 10.5μl. The mixture was then incubated at 37ºC for 40 min. 
Next, 1μl of 0.02M EDTA was added followed by an incubation at 65ºC for 10 
min. Random priming was carried out by adding 0.5μl of random primers and 
incubating at 65ºC for 10 min and then placed on ice. For reverse transcription, 
the random-primed RNA was split into 2 tubes – RT+ and RT- (6μl each) and 6μl 
of deionized water, 4μl of 5 X first strand buffer, 2μl of 0.1M DTT and 1μl 
dNTPs were added into each tube. The tubes were then incubated at 25ºC for 10 
Chapter 2: Materials and Methods 
 
 43
min followed by 42ºC for 2 min after which 1μl of reverse transcriptase was 
added to the RT+ tube. The tubes were then incubated at 42ºC for 50 min, 70ºC 
for 10 min and stored at -20ºC.  
 
2.4 Real-time PCR 
The five cDNA standards used were undiluted cDNAs synthesized from 
total RNA of untreated MN9D cells. Standard and test cDNA templates were 
added with SYBR green master mix, specific sets of primers (nm23-M2 mRNA: 
NdpkB(28)-Forward: 5’-CCT CGAGCG TAC CTT CAT TGC-3’ and 
NdpkB(154)-Reverse: 5’-TTC AGA GGC CCG AAG GAA C-3’; HPRT mRNA: 
mHPRT-Forward: 5’-GAA TCT GCA AAT ACG AGG AGT CCT-3’ and 
mHPRT-Reverse: 5’-CCT TAC TAG GCA GAT GGC CAC A-3’), and sterile 
water to top up to total volume of 50μl. The PCR mixtures were aliquoted to 
MicroAmp optical 96-well reaction plate (Applied Biosystems, USA). The 96-
well reaction plate were placed in the ABI Prism 7000 sequence detection system 
(Applied Biosystems, USA) and PCR reaction was started with 50°C for 2 min, 
followed by 95°C for 10 min and then continued with 40 cycles of 95°C for 15 sec 
and 60°C for 1 min. A melting curve was obtained for each PCR product after 
each run to confirm that the signal corresponded to a unique amplicon of the 
predicted size. The specificity of the PCR product was verified by DNA 
sequencing. Expression levels were obtained by subtracting the value for each 
sample in the absence of reverse transcriptase from the corresponding value in the 
presence of reverse transcriptase and then normalizing to the housekeeping gene 
encoding Hypoxanthine-Guanine Phosphoribosyl Transferase (mHPRT), obtained 
for every sample in parallel assays in two to four independent experiments. The 
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real-time PCR results were then analyzed using ABI Prism 7000 Sequence 
Detection System Software version 1.0 (Applied Biosystems, USA).   
 
2.5 Transfection of plasmid construct to mammalian cells 
For transient transfection in over-expression experiments, 2 x 105 cells 
were plated in 6-well plate (Corning, USA) and grown to 90-95% confluent at the 
time of transfection. The plasmid DNA to be transfected into the cells and 
lipofectamine 2000 was diluted in DMEM without serum individually. Both were 
mixed gently and incubated for 20 min at room temperature. The complexes were 
then added to each well containing the cells and medium. The cells were 
incubated at 37°C for 48 hr prior to testing for transgene expression. After 48 
hours, the cells were collected and processed for the respective experiments. 
Transcriptional levels of nm23-M2, Cyclin D1 and β-Actin were investigated by 
RT-PCR using specific primers (nm23-M2 mRNA: NdpkB(28)-Forward: 5’-CCT 
CGAGCG TAC CTT CAT TGC-3’ and NdpkB(154)-Reverse: 5’-TTC AGA 
GGC CCG AAG GAA C-3’, cycD1(191)-Forward: 5’-ACA CCA ATC TCC 
TCA ACG A-3’ and cycD1(815)-Reverse: 5’-TAG CAG GAG AGG AAG TTG 
T-3’, β-Actin(214)-Forward: 5’-TGG GAA TGG GTC AGA AGG AC-3’ and β-
Actin(689)-Reverse: 5’-TGT GGT GGT GAA GCT GTA GCC-3’). 
 
2.6 Protein work 
2.6.1 Isolation of total cell lysate 
MN9D cells subjected to various control and experimental conditions were 
washed twice with PBS to remove the residual culture medium and followed by 
lysing the cells with a volume of 50-200μl of lysis buffer (100mM HEPES, 
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150mM NaCl, 5mM MgCl2, 1mM EDTA and 1% Triton X-100). Total cell 
lysates were collected and incubated overnight at -20°C. Cell debris was removed 
by centrifugation at 12,000 x g for 5 min at 4°C and the supernatant was stored at 
-20°C for later use.  
 
2.6.2 Bio-Rad Bradford protein quantification assay  
Protein concentration was determined by Bio-Rad Bradford assay kit (Bio-
Rad, USA). Standard protein solutions were prepared by using bovine serum 
albumin (BSA) diluted to concentration of 5 mg/ml, 10 mg/ml, 15 mg/ml, 20 
mg/ml and 25 mg/ml, respectively, to obtain the standard curve for determination 
of the protein concentration of the unknown samples. A volume of 25μl of 
Bradford assay solution was added to 100μl of each of the protein samples of 
known dilution factor as well as the standards. The mixtures were incubated at 
room temperature for 5 min before the optical density was determined at 595nm.  
The concentration was measured by SpectraMax 250 spectrophotometer and 
analysed by SOFTmax Pro Life Sciences Edition software (Molecular Devices). 
The protein concentrations of the samples were determined by using its optical 
density value to plot against the standard curve. 
 
2.6.3 Protein separation using sodium dodecyl sulphate-
polyacrylamide electrophoresis (SDS-PAGE) 
 The protein samples were normalized to a standard concentration of 20-
40mg/ml by diluting with sterile water and the required amount were mixed with 
the 4X loading buffer {100mM Dithiothreithol (DTT, Bio-Rad, USA), 160mM 
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Tris pH 6.8, 4% SDS, 20% glycerol and 0.1% bromophenol blue}. The mixtures 
were boiled at 95oC for 5 min to denature the proteins. The pre-calculated 
amounts of each protein sample were then loaded into the wells of a 12-15% SDS-
PAGE gel and subjected to a constant voltage of 80V (stacking gel part) or 120V 
(resolving gel part) for 1.5-3.0 hr in 1X running buffer (192mM glycine, 25mM 
Tris and 0.1% SDS). The SDS-PAGE gels were casted using the Bio-Rad protein 
mini-gel apparatus (Bio-Rad, USA). 10 ml of 12% w/v resolving gel and 4 ml of 
4% stacking gel were prepared as in Table 2.1. APS (ammonium persulphate) and 
TEMED (N, N, N, N-tetramethylethylene-diamine) were added after the gel 
mixture was degassed. The resolving gel was poured into the space between the 
two plates to a height such that it was about 5mm from the bottom of the comb. 
The gel was layered with isopropanol to allow the polymerization of 
polyacrylamide. After the resolving gel was set, the isopropanol was decanted and 
the excess was absorbed by a slide of filter paper. The stacking gel was poured 
above the resolving gel and the comb was inserted. The gel was allowed to 
polymerize for about 30 min.  
After electrophoresis, the gel was stained in 50ml of staining solution 
(10% acetic acid, 45% isopropanol, 0.1% Coomassie brilliant blue) for 30 min for 
visualization of the protein bands. The gel was then destained in destaining 
solution (10% (v/v) methanol; 10% (v/v) acetic acid) for several hours to 
overnight by gently shaking. 
 
2.6.4 Western immunoblot analysis 
Protein separation was performed using SDS-PAGE in 12-15% gels as 
described above. The proteins were then transferred to nitrocellulose membranes 
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(Bio-Rad, USA) using an electro-blotting apparatus (Bio-Rad, USA) at a constant 
voltage of 85V for 1.5 hr in the western transferring buffer (7.202g of glycine, 12 
ml of 1M Tris-HCl (pH 7.4), 20% methanol). After the proteins were transferred, 
the membranes were stained with Ponceau S dye (Sigma, USA) to visualize the 
protein bands. After rinsing the membranes with Tris buffer saline (TBS) (27ml of 
5M NaCl, 12ml of 1M Tris-HCl pH 7.4) to remove the red stain, the blots were 
blocked overnight in a blocking buffer {TBS + 0.1% Tween-20 (TBS-T) + 5% 
BSA (Albumin fraction V from bovine serum, Merck, Germany) or non-fat dry 
milk}. After blocking out non-specific binding, the blots were then incubated with 
a primary antibody in TBS-T + 2% BSA or non-fat dry milk at 40C overnight with 
gently shaking. All the blots were washed five times at 5 min each with TBS-T 
and then incubated with the secondary antibodies {anti-rabbit-HRP (1:1000) or 
anti-mouse-HRP (1:1000)} against the primary antibodies for 1-2 hr at room 
temperature. The unbound antibodies were removed by five washes with TBS-T 
for 5 min each at room temperature. The blots were finally developed with the 
enhanced chemiluminescent (ECL) kit (Pierce Biotechnology, USA) and the 
signals were detected on Pierce films (Pierce biotechnology, USA). Respective 
primary antibodies used were: Cyclin D1 (DCS6) mouse monoclonal antibody 
(Cell Signaling, USA), Mouse monoclonal Anti-β-Tubulin Clone 2-28-33 
antibody (Sigma, USA), c-Myc (C-8) mouse monoclonal antibody: sc-41, GFP 
(FL) rabbit polyclonal HRP conjugate antibody: sc-8334 HRP, Oct-1 (C-21) 
rabbit polyclonal IgG antibody: sc-232, SNAP-25 (SP12): sc-20038 antibody 
(Santa Cruz Biotechnology, USA), respective secondary antibodies used were: 
goat anti-rabbit IgG HRP: sc-2004, goat anti-mouse IgG HRP: sc-2005 (Santa 
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Cruz Biotechnology, USA). The different blotting conditions and antibody 
applications are indicated on Table 2.2. 
2.7 Subcellular fractionation 
Subcellular fractionation of the MN9D cells was carried out using 
BioVision Nuclear / Cytosol Fractionation Kit (BioVision, USA) as recommended 
by the manufacturer. This Nuclear / Cytosol Extraction Kit provides a complete 
system that enables the separation of nuclear extract from the cytoplasmic fraction 
of mammalian cells. The MN9D cells were collected by centrifugation at 600 x g 
for 5 min at 4°C and the supernatant was discarded. A volume of 0.2ml Cytosol 
Extraction Buffer (CEB)-A mix containing DTT and Protease Inhibitors were 
added to the cell pellet and were vortexed vigorously to re-suspend the cell pellet. 
The tube was incubated on ice for 10 min. A volume of 11μl of ice-cold Cytosol 
Extraction Buffer (CEB)-B was added to the tube, vortexed for 5 sec and 
incubated on ice for 1 min. The tube was then vortexed for 5 sec and centrifuged 
for 5 min at maximal speed. The supernatant (cytoplasmic extract) fraction was 
then transferred to a clean pre-chilled tube. The pellet was re-suspended in 100μl 
of ice-cold Nuclear Extraction Buffer (NEB) Mix. The tube was vortexed for 15 
sec and returned to ice while continuing vortexing for 15 sec every 10 min, for a 
total of 40 min. Next, the tube was centrifuged at full speed for 10 min. The 
supernatant (Nuclear extract) was immediately transferred to a clean pre-chilled 
tube and placed on ice. All extracts were stored at -80°C until use. 
 
2.8 Fluorescence microscopy and neurite assay 
Cells were plated at a density of 105-106 on 6-well plate (Corning, USA). 
Individual wells transfected with the null plasmid and pcDNA3.1(-)_fl nm23-
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M2_GFP plasmid. The cells were stained with Hoechst dye for 5 min to stain the 
nucleus and fixed in 0.5% paraformaldehyde in 1X PBS, pH 7.4 for 30 min at 
room temperature after 2 days post-transfection. The cells were then examined 
with Zeiss Axiovert 25CFL inverted microscope and photographs of cells were 
captured using DP controller, Olympus (Olympus, USA). The proportion of 
neurite-bearing cells was counted using a phase-contrast microscope at 200X 
magnification. The cell images were analyzed using ImageJ software version 
1.34s (by Wayne Rasband, National Insitute of Health, USA). The length of the 
primary neurite was defined as the distance from the soma to the tip of the longest 
branch. Processes longer than 1.5 times of the cell body diameters were counted 
as neurites. For every datum point, the mean value was calculated from five 
random field observations of three replicate experiments, and at least 150 cells 
were counted per field.  
 
2.9 Flow cytometry 
Cells were plated at a density of 105-106 on 6-well plate (Corning, USA). 
Each wells were transfected with the null plasmid, pcDNA3.1(-)_fl nm23-
M2_GFP individually. Cells in one well were differentiated using n-butyric acid 
as mentioned. The cell culture medium was discarded and the cells were washed 
twice with 1X PBS. The cells were trypsinized and harvested with fresh DMEM 
culture medium by pipetting into 15ml Falcon tubes, followed by centrifugation at 
1,500 x g for 10 min at 40C. The supernatant was discarded and the pellet was 
washed with 5ml of 1X PBS. The cell pellet was re-suspended with 1X PBS and 
spun down for another 10 min at 40C. The supernatant was decanted and the pellet 
was fixed with 0.5% paraformaldehyde for 5 min on ice to prevent GFP leakage. 
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The samples in the tubes were centrifuged again and the paraformaldehyde was 
discarded. The cell pellets were re-suspended with 0.5ml of PBS and added drop 
by drop with 4.5ml of ice-cold (pre-chilled at –200C) 70% ethanol. After which, 
the cells in the tubes can be stored up to 1 month at –200C until proceeding to 
flow cytometry. 
The distribution of the cells in G0, G1, S, and G2/M cell cycle phases was 
determined by DNA flow cytometry or Fluorescence Activated Cell Sorting 
(FACS). Before proceeding to flow cytometry, the stored cells were centrifuged at 
2,700 x g for 10 min at 4°C and the ethanol was then discarded. The cell pellets 
were re-suspended with PI staining solution {Stock solution of 1g glucose and 1 
litre PBS (filtered and sterilized) with propidium iodide (50µg/ml) (Sigma, USA) 
in presence of RNase A (50mg/ml) (Sigma, USA)} and incubated in dark at room 
temperature for 30 min. The cell samples were filtered through the 41um nylon 
filter and then subjected to flow cytometry. Flow cytometric analysis was carried 
out on 20,000 cells using EPICS Elite ESP cytometer (Beckman Coulter, USA). 
The FACS data were then analyzed and the histogram plotted using WinMDI 
(Windows Multiple Document Interface for Flow Cytometry Application version 
2.8 by Dr. Joseph Trotter, La Jolla, CA). 
 
2.10 siRNA interference 
MN9D cells in 6-wells plate (Corning, USA) were transfected as followed. 
The siRNA (nm23-M2_RN: r(GAA CAC CUG AGC AGC AUU)d(TT) (Qiagen, 
USA) recognized the target sequence in nm23-M2 sequence: 5’-AAG AAC ACC 
TGA AGC AGC ATT-3’) were transfected into cells. For each well, 1.2µg of 
siRNA was used. The ratio of amount of siRNA used to RNAiFect transfection 
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reagent is 1 : 6. First, 4.8μl of siRNA stock was diluted with 95.2μl of Buffer EC-
R and mixed by vortexing. Next, 7.2μl of RNAiFect transfection reagent was 
added and mixed by pipetting up and down five times. The mix was then 
incubated for 10 to 15 min at room temperature to allow for complex formation 
before adding to the cells. The culture medium from the plate was first aspirated 
and 3ml of fresh culture medium containing serum and antibiotics was added to 
the cells. The complexes were added drop-wise onto the cells and the plate was 
swirled gently to ensure uniform distribution of the transfection complexes. The 
cells were then incubated with the transfection complexes under normal growth 
conditions. After 24 hr incubation, the cells were harvested and the total RNA was 
extracted by using RNeasy Mini Kit (Qiagen, USA) as mentioned in section 2.2.1. 
The gene silencing of nm23-M2 at the mRNA level was monitored after 24 hr by 
RT-PCR using the specific primers (nm23-M2 mRNA: NdpkB(28)-Forward: 5’-
CCT CGAGCG TAC CTT CAT TGC-3’ and NdpkB(154)-Reverse: 5’-TTC AGA 
GGC CCG AAG GAA C-3’). After siRNA interference, the protein levels of 
SNAP-25 and cyclin D1 in sodium butyric acid-treated MN9D cells were 
















Figure 2.1 Plasmid map and sequence reference points of pGEM-T Easy 
cloning vector. (The figure is reproduced from Promega, 















Figure 2.2 Plasmid map and sequence reference points of pcDNA3.1(+/-) 
cloning vector. (The figure is reproduced from website of 


















Preparation of SDS-PAGE gel  
  
12% Resolving gel component Volume (ml) 
30% Bis-acrylamide 4 
Tris-HCl pH 8.8 2.5 
MilliQ water 3.39 
10% Ammonium persulphate 0.1 
TEMED 0.01 
  
4% Stacking gel component Volume 
30% Bis-acrylamide 0.455 
Tris-HCl pH 6.8 0.875 
MilliQ water 2.1315 



































Table 2.1 Preparation of SDS-PAGE gel with the listed required components.  



















5% non-fat milk, 
30min at RT  
Overnight at 
4oC 
β-Tubulin Sigma (USA) 1:1000, 2% 
non-fat 
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 Table 2.2 Primary and secondary antibodies application for western blotting
in this thesis.  
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3.1 Cloning and characterization of full-length nm23-M2 cDNA 
 
3.1.1 Cloning of full-length pcDNA3.1(-)_fl nm23-M2_GFP and 
pcDNA3.1(-)_fl nm23-M2_MYC 
 
Figure 3.1 shows an agarose gel electrophoresis photograph on the total RNA 
isolated from undifferentiated MN9D cell lines. The photograph image shows the 
presence of two band fragments, where 28S rRNA fragment band was higher than 
18S rRNA fragment band. The integrity of the total RNA was also determined by the 
intensity of the 28S rRNA band relative to the intensity of 18S rRNA band. The 
intensity of the upper 28S rRNA band was 1.5 – 2 times higher than the intensity of 
lower 18S rRNA band which indicated that the total RNA was not degraded during 
the experimental procedure of total RNA isolation.  
In order to clone the full-length nm23-M2 cDNA, the nucleotide coding 
sequence of nm23-M2 should be known and specific primers were designed to prime 
out the specific nm23-M2 cDNA product. The PCR amplification to generate full-
length nm23-M2 cDNA insert was carried out using Access RT-PCR System 
(Promega, USA) with 1 sets of specific primers (NdpkB-Forward: 5’-ATG GCC 
AAC CTC GAG CGT-3’ and NdpkB-Reverse: 5’-CTA CTC GTA CAC CCA GTC-
3’) and the template used was the total RNA isolated from undifferentiated MN9D 
cells. The full-length nucleotide sequence of nm23-M2 (NM_008705) and the 
annealing site of the specific primers are shown in figure 3.2. The PCR product was 
analyzed by DNA agarose electrophoresis and shown in figure 3.3. The PCR product 
was also sent for capillary sequencing to confirm its identity as full-length nm23-M2 
cDNA. 
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 The full-length nm23-m2 PCR product was TA cloned into pGEMT-Easy 
vector. Colony PCR screening as mentioned in section 2.2.6 was carried out using T7 
and SP6 primers to prime out the cloned insert into pGEMT-Easy vector. In order to 
double check for the positive clones which contained the full-length nm23-m2 insert, 
restriction enzymes, XbaI and EcoRI were added to cut out the insert from pGEMT-
Easy vector. The samples were then analyzed by DNA agarose electrophoresis and 
shown in figure 3.4. 
PCR amplification of the full-length nm23-M2 gene using pGEM-
TEasy_mNm23-M2 plasmid as a template with the following set of specific primers 
(NdpkB(XbaI+KS)-Forward: 5’-GGG CCC TCT AGA ACC ATG GCC AAC CTC 
GAG CGT A-3’ and NdpkB(Stop+EcoRI)-Reverse: 5’-GTG GTG GAA TTC CTC 
GTA CAC CCA GTC ATG-3’. The amplified DNA product was then digested with 
the restriction enzymes XbaI and EcoRI and ligated into the pcDNA3.1(-)_GFP and 
pcDNA3.1(-)_MYC vector. In order to choose for positive clones that contained the 
full-length nm23-M2 insert, restriction enzymes, XbaI and EcoRI were added to cut 
out the insert from individual pcDNA3.1(-) vector. The samples were then analyzed 


















   1 ggacagagac gactggcaag accaggcagc ctgagcgtnc cgggttgggc agcggggtcc 
 61 tccggggtgt ggcgtctctc gtcccgcccc gcgtccctcc tctctccgcg ccggctggtg 
121 gtcgttctat tctctttgct tctgtcgctc atcgcagaca ccagccgacc caccggcttt 
 
NdpkB-Forward: 
        5’ATGG CCAACCTCGA GCGT  
181 cggaccatgg ccaacctcga gcgtaccttc attgccatca agccagatgg cgtgcagcgc 
241 ggcctggtgg gcgagatcat caaacggttc gagcagaagg ggttccgcct ggtggccatg 
301 aagttccttc gggcctctga agaacacctg aagcagcatt acatcgacct gaaagaccgt 
361 cctttcttcc cggggctggt gaagtacatg aactcggggc ccgtggtggc catggtctgg 
421 gaggggctca atgtggtgaa aacgggccga gtgatgctgg gggagaccaa tccagctgat 
481 tcaaaaccag gcaccatccg tggggatttc tgcattcaag ttggcaggaa catcattcat 
541 ggcagtgatt cagtggagag tgctgagaaa gagatccatc tgtggtttaa gcccgaagaa 
601 ctgatcgact acaagtcttg tgcccatgac tgggtgtacg agtagacatg aagaaaccag 
            AC TGGGTGTACG AGTAG 5’        
   (NdpkB-Reverse: 5’-CTACT CGTACACCCAG TC-3’) 
 
661 aatccttttc agcactactg atgggtttct ggacagagct cttcatccca ctgacaggat 















     A   B       C      D      E       F      G     H      I        J       K       L 
Figure 3.1 Total RNA isolation. A photograph image of an agarose gel
under UV light excitation showing the presence of total RNA
isolated from undifferentiated MN9D cell line (Lane A to D),
differentiated MN9D cell line (Lane E to L).   
Figure 3.3 RT-PCR amplification of full-length nm23-M2 cDNA. A
photograph image of an agarose gel under UV light
excitation showing 100bp DNA ladder (Lane A) and nm23-
M2 PCR product ~458bp (Lane B).
458bp nm23-M2 PCR product 
Figure 3.2 NM_008705 nm23-M2 mRNA. The coding sequence of nm23-M2 is
highlighted in yellow and specific primer annealing sites are indicated for
cloning of the full-length cDNA. 
































458bp nm23-M2 PCR product
pGEMT-Easy vector 
Figure 3.4 Restriction enzyme digestion of pGEM-T Easy_mNm23-M2
recombinant plasmid. A photograph image of an agarose gel
under UV light excitation showing 100bp DNA ladder (Lane
A), positive pGEMT-Easy vector clones containing nm23-M2
insert (Lane B-E), negative clones without the insert (Lane F)
and 1kBp DNA ladder (Lane G). 
Figure 3.5 Restriction enzyme digestion of pcDNA3.1(-)_mNm23-M2
recombinant plasmid. A photograph image of an agarose gel
under UV light excitation showing positive pcDNA3.1(-)_GFP
vector clones containing nm23-M2 insert (Lane A, C-E),
negative pcDNA3.1(-)_GFP vector clones without the insert
(Lane B), positive pcDNA3.1(-)_MYC vector clones containing
nm23-M2 insert (Lane F-J) and 1kB DNA ladder (Lane K).
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3.1.2 Routine tissue culture 
  
Both undifferentiated and differentiated MN9D cell lines were routinely 
cultured for the extraction of total RNA from both phenotypes and for transfection of 
recombinant plasmids for overexpression and siRNA interference studies. In order to 
differentiate MN9D hybrid cell line into mesencephalic dopaminergic neurons, the 
supplement of DMEM culture medium with the addition of 1mM of n-butyric acid 
was essential. Morphological characteristics of both undifferentiated and 
differentiated MN9D cell lines at day 0-7 are shown in figure 3.6. Differentiated 
MN9D cells have different morphological characteristics with undifferentiated 
MN9D cells as they can be recognized by the presence of interconnecting neurite 
outgrowth and flattened appearance while undifferentiated MN9D cells are relatively 
more rounded in shape as compared to those differentiated MN9D cells. From day 1 
onwards, MN9D cells which were treated with 1mM n-butyric acid started to change 
its morphological appearance as most of the cells were exhibiting a flattened 
appearance. Neurite outgrowth began from day 2 onwards as more cells showed 
extension of neurites and longer neurite extension were observed during the 6th and 
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Figure 3.6 MN9D time-course differentiation. A panel of photographs
showing the morphological appearance of MN9D cells with and
without treatment of 1mM n-butyric acid for differentiation induction
in a time course of 7 days. 
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3.1.3 Temporal expression of nm23-M2 in MN9D cells 
 The endogenous levels of nm23-M2 in differentiating MN9D cells from day 1 
to day 7 upon addition of 1mM n-butyric acid were investigated using quantitative 
real-time PCR. It is the most sensitive and reliable method for the detection and 
quantification of nucleic acids levels. The cDNAs of differentiating MN9D cells from 
day 1 to day 7 were reverse-transcripted from total RNA isolated from MN9D cells 
harvested at day 1 to day 7 respectively. Specific real-time PCR primers were 
designed to amplify a small fragment of the full-length nm23-M2 gene. The SYBR 
green dye allows detection of any double-stranded DNA generated during PCR. 
Reactions were characterized by the point in time during cycling when amplification 
of a PCR product is first detected rather than the amount of PCR product accumulated 
after a fixed number of cycles. The higher the starting copy number of the nucleic 
acid target, the sooner a significant increase in fluorescence is observed. Model of a 
single amplification plot showing terms commonly used in real-time quantitative PCR 
are shown in figure 3.7 and the multiple amplification plots during the real-time PCR 
run were captured in figure 3.8. The real-time analysis of nm23-M2 PCR product was 
carried out using the ABI Prism SDS software and the graphical representation of the 
results are shown in figure 3.9. 
 
Figure 3.7 Model of a single amplification plot used in real-time PCR
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Figure 3.8 A graph showing multiple amplification plots during the 
real-time PCR run.  
Figure 3.9 A graphical representation showing changes in
endogenous mRNA level of nm23-M2 post-induction of
MN9D cells with 1mM n-butyric acid. The results were
derived from 3 sets of experimental replication. 
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 The bar chart in figure 3.9 showed that the relative quantity of endogenous 
nm23-M2 in MN9D cells was the highest at the 6th day upon addition of 1mM n-
butyric acid. This further confirmed that nm23-M2 endogenous mRNA level was up-
regulated during differentiation of MN9D cells which coincide with the previous 
micro-array studies.  
 
 
3.1.4 Spatial expression of nm23-M2 in MN9D and SH-SY5Y cells 
MN9D and SH-SY5Y cells were transfected with the control null plasmid and 
pcDNA3.1(-)_fl nm23-M2_GFP plasmid. The gene expression was examined under a 
fluorescent microscope after 48hr incubation, while photographs of the both 
transfected cell lines were captured and are shown in figure 3.10. The fluorescence 
detected in the photographs indicated that exogenous GFP proteins were expressed in 
these cells. For cells that were transfected with the control null plasmid, they 
exhibited general GFP expression in the whole cell bodies including the nucleus and 
cytoplasm. For cells that were transfected with pcDNA3.1(-)_fl nm23-M2_GFP 
plasmid, GFP expression was only exclusive to the cytoplasm but not the nucleus. 
This observation led to the conclusion that pcDNA3.1(-)_fl nm23-M2_GFP plasmid 
only localized in the cytoplasm but not in the nucleus in both MN9D and SH-SY5Y 
cell line. This indicated that the localization of the nm23-M2 does not differ in 
different cell types as illustrated in both the mouse MN9D cell line and the human 
SH-SY5Y cell line. 
Western immunoblot analysis using anti-GFP antibody were also carried out 
on extracted MN9D cell protein lysate to indicate that the transfections of individual 
recombinant vectors were performed successfully and the western blot results are 
shown in figure 3.11. 
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Figure 3.10 Spatial expression of nm23-M2 in MN9D and SH-SY5Y cells. 
A panel of photographs indicating MN9D and SH-SY5Y cells
transfected with individual null pcDNA3.1(-) plasmid vector and
pcDNA3.1(-)_fl nm23-M2_GFP plasmid vector. Fluorescein
isothiocyanate (FITC) filter were used to detect GFP fluorescence.
Hoechst stain to indicate nucleus staining. 
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      Lane: 











 In the western blot as shown in figure 3.11, we can confirm that the 
transfections of the two plasmids, 1) control null GFP plasmid (pcDNA3.1(-)_GFP) 
and 2) pcDNA3.1(-)_fl nm23-M2_GFP plasmid, were performed successfully as we 
can detect the GFP protein bands by using anti-GFP antibody. The protein size of 
control null GFP plasmid is around 30kDa. The full-length nm23-M2 gene insert was 
added to form pcDNA3.1(-)_fl nm23-M2_GFP plasmid and the GFP protein band 
was detected at around 47kDa (shown in Lane 3) as the protein size of nm23-M2 is 
around 17kDa.  
 
3.1.5 Subcellular localization of nm23-M2 
The purpose of cloning nm23-M2 into pcDNA3.1(-)_MYC plasmid and 
transfecting it into MN9D and SH-SY5Y cells was to investigate the subcellular 
localization of nm23-M2 in both different cell types. This was achieved by carrying 










Figure 3.11 Western immunoblot analysis of GFP in MN9D cells transfected
with pcDNA3.1(-)_GFP plasmid (Lane 2) and pcDNA3.1(-)_fl
nm23-M2_GFP plasmid (Lane 3). Lane 1 denotes Precision Plus
Protein Standards. 
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cytoplasm fractions separately. The individual protein fraction was resolved by 
protein SDS-PAGE and probed with C-Myc and Oct-1 antibodies as shown in figure 
3.12.  
 
Cell lines:  MN9D                    SH-SY5Y 
     
 Fractions:  Cytosol          Nuclear           Cytosol       Nuclear  
 
  
 Oct-1         








 Oct-1, a transcription factor which is a member of the POU homeodomain 
family plays an important role in activating the transcription of various genes that 
contain an Oct-1 binding motif, ATGCAAAT (Sturm et al. 1988). Oct-1 transcription 
factors are known to localize mainly in the nucleus of the cells. The results shown in 
figure 3.12 also confirmed that the fractionation was carried out properly as Oct-1 
protein bands were prominent in the nuclear fractions of both cell lines. As the full-
length nm23-M2 was tagged with the C-Myc protein fragment, we can conclude that 
nm23-M2 localized mainly in the cytosolic fractions in both mouse and human cell 
types. This observation also corresponds to the fluorescence photographs in figure 
3.10 that nm23-M2 localized mostly in the cytoplasm but lesser in the nucleus of the 
cells. There is a possibility that nm23-M2 localized in the nucleus as there are reports 
Figure 3.12 Western immunoblot analysis of Oct-1 and C-Myc antibodies in
subcellular fractions of MN9D and SH-SY5Y cell lines. 
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suggesting that nm23 gene, particularly, nm23-H2 acts as transactivating factor to 
activate transcription (Postel et al. 1993). 
 
3.2 Overexpression studies of nm23-M2 in MN9D cells 
3.2.1 Morphological appearance of MN9D overexpressing 
pcDNA3.1(-)_fl nm23-M2_GFP 
 The morphology of MN9D cells overexpressing the full-length nm23-M2 
gene were investigated by transfecting the cells with pcDNA3.1(-)_fl nm23-M2_GFP 
plasmid. The experimental control used was MN9D cells transfected with a null GFP 
plasmid (pcDNA3.1(-)_GFP). After 48hr post-transfection, the cells were taken out 
from the CO2 incubator and placed under fluorescent microscope for phototaking. 
The photographs taken are shown in figure 3.13. From the pictures shown in figure 
3.13, cells that were transfected with the null GFP plasmid did not show any changes 
in the cell morphology, which corresponded to the typical morphology of 
undifferentiated MN9D cells. The cells still remained relatively rounded in shape and 
tend to aggregate together in small clumps of cells. Whereas for cells that were 
transfected with pcDNA3.1(-)_fl nm23-M2_GFP plasmid, morphological appearance 
was obviously different from the undifferentiated MN9D cells as more cells were 
exhibiting a flattened appearance and neurite outgrowth was observed. The cells were 
much similar to those differentiated cells after being treated with 1mM of n-butyric 
acid as shown in figure 3.6. 
 The number of transfected MN9D cells bearing neurites were also counted 
and the data were then analyzed and plotted into a bar chart as shown in figure 3.14. 
The bar chart showed that MN9D cells that were transfected with pcDNA3.1(-)_fl 
Chapter 3: Results 
 
 71
nm23-M2_GFP had significantly more cells with neurites than MN9D/null GFP 
plasmid. 
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Figure 3.13 Morphology of transfected MN9D cells. A panel of fluorescent
microscopy photographs showing the morphological appearance of
MN9D cells overexpressing null GFP plasmid (upper panel) and full-
length nm23-M2 tagged with GFP plasmid (lower panel). Cells
overexpressed with nm23-M2 displayed a flattened appearance with
neurite outgrowth. 
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3.2.2 MN9D cells showed cell growth arrest when treated with n-
butyric acid and transfected with nm23-M2  
Flow cytometry analysis of EGFP-positive cells by FACS was carried out to 
examine the cell cycle stages of MN9D cells in both cases when 1) they were treated 
with 1mM of n-butyric acid and 2) they were transfected with the full-length nm23-
M2. Upon treatment with 1mM n-butyric acid, MN9D cells exhibited a mature 
neuronal morphology, characterized by a flattened cell body and the extension of 
neurites. There was a decrease in the doubling time of the treated cells (data not 
shown), indicating they were exiting the cell cycle, as a result of differentiation. This 
was accompanied by an increase in G1-phase stage cells when the cells were treated 
with n-butyric acid as shown in figure 3.15 and 3.16. MN9D cells that were 
*
Figure 3.14 A graph showing the morphological changes of MN9D cells after 2 days
post-transfection of nm23-M2. MN9D cells transfected with nm23-M2
had significantly more cells with neurites than MN9D/null GFP plasmid
as determined by Student’s T-test using SPSS statistical software.
*P<0.05.  
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transfected with nm23-M2 plasmid construct also exhibited an increase in G1-phase 
stage cells. This was confirmed by an arrest of differentiated cells in the G1 phase as 
















G0 G1 S G2/M
MN9D Control 1.84 44.94 24.21 28.98
MN9D treated with n-butyric acid (1mM) 12.45 63.66 5.53 17.8
MN9D transfected with pcDNA3.1-GFP null plasmid 3.23 47.13 22.59 25.97
MN9D transfected with Nm23-M2-GFP plasmid 4.34 56.57 20.89 17.23
Graph showing percentage of cells in null plasmid and  nm23-M2 






















GFP null plasmid transfection Nm23-M2 plasmid transfection
*
Figure 3.16 A graph showing the percentage of MN9D cells after 2 days post-
transfection of GFP null plasmid and nm23-M2 plasmid. MN9D cells
transfected with nm23-M2 had significantly more cells at G1 phase than
MN9D/null plasmid as determined by Student’s T-test using SPSS
software. *P<0.05. 
Figure 3.15 A table showing the percentage of MN9D cells at different stages
of the cell cycle in different conditions. 
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3.2.3 SNAP-25 protein expression was up-regulated in MN9D cells 
overexpressing pcDNA3.1(-)_fl nm23-M2_GFP 
 Proteins associated with the presynaptic terminal play critical roles during 
neurite outgrowth and synaptogenesis. SNAP-25 (Synaptosomal-associated protein of 
25 kDa) is an essential component of the core complex that mediates presynaptic 
vesicle trafficking and is directly involved in the release of neurotransmitters. It also 
interacts with syntaxin and synaptobrevin through its N-terminal and C-terminal α-
helical domains. In previous studies by other investigators, it was shown that 
expression of the protein, SNAP-25, is sufficient to induce neuronal differentiation. 
Both the expression of SNAP-25 and its subcellular distribution are linked closely 
with the transformation of growth cones to synaptic terminals (Catsicas et al. 1991). 
Antisense oligonucleotides of SNAP-25 block neuritic elongation in rat cortical 
neurons and PC-12 cells in vitro, and in amacrine cells of the developing chick retina 
in vivo (Osen-Sand et al. 1993). Furthermore, overexpression of SNAP-25 itself 
enhanced neurite elongation in PC-12 cells (Zhou et al. 2000). Hence, the protein 
expression level of the phenotypic marker of maturation, SNAP-25 was chosen to be 
examined in MN9D cells overexpressing pcDNA3.1(-)_fl nm23-M2_GFP, to test the 




























 The western immunoblot in figure 3.17 showed that the level of SNAP-25 
protein was higher in both cases where a) MN9D cells treated with n-butyric acid 
(Lane 2) as compared to the MN9D with mock transfection (Lane 1) as control, b) 
MN9D cells transfected with MN9D transfected with pcDNA3.1(-)_fl nm23-
M2_GFP (Lane 4) as compared to MN9D transfected with null GFP plasmid (Lane 3) 
as control. Analysis of this immunoblot confirmed that the morphological 
differentiation of MN9D cells was accompanied by an increase in protein expression 





Figure 3.17 Western immunoblots showing overexpression results after 48hr of
transfection using mouse anti-SNAP-25 monoclonal antibody and mouse
anti-β-tubulin monoclonal antibody as loading control. Lane: 1) MN9D
with mock transfection, 2) MN9D treated with 1mM n-butyric acid, 3)
MN9D transfected with null GFP plasmid as control, 4) MN9D
transfected with pcDNA3.1(-)_fl nm23-M2_GFP. The blot was from one
experiment representative of three similar repeats. 
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3.2.4 Cyclin D1 mRNA and protein expression was down-regulated 
in MN9D cells overexpressing pcDNA3.1(-)_fl nm23-M2_GFP 
 A hallmark of terminal differentiation is an irreversible arrest in the G0/G1 
phase of the cell cycle. This arrest involves the coordinate regulation of signals that 
negatively control the cell cycle machinery and inhibit the G1/S transition. The G1/S 
transition is known to be sequentially controlled by D-type cyclins, which activate 
cyclin-dependent kinases, CDK4 and CDK6, and subsequently by cyclin E, which 
associates with CDK2 (Grana and Reddy, 1995). CDK activity is dependent on 
association with cyclins and subsequent phosphorylation-dephosphorylation events, 
and may be inhibited by 2 different groups of CDK inhibitors (CKIs), namely the 
Ink4 family and the Cip/Kip family (Vidal and Koff, 2000). Thus, growth arrest 
associated with differentiation could be achieved by several mechanisms including 
the down-regulation of cyclins or up-regulation of CKIs or both. In the previous 
section 3.2.2, MN9D cells when overexpressing pcDNA3.1(-)_fl nm23-M2_GFP 
showed cell growth arrest where there was a significant increase in the percentage of 
G1 phase staged cells. Therefore, the mRNA and protein level of the G1 phase cell 
cycle key regulatory gene, cyclin D1 will be studied in this section.  
 The mRNA and protein levels of cyclin D1 were examined by RT-PCR and 
western immunoblot using anti-cyclin D1 antibody, respectively as shown in figure 
3.18. Both the mRNA and protein levels of cyclin D1 were down-regulated in MN9D 
cells treated with 1mM n-butyric acid (Lane 2) and MN9D cells transfected with 
pcDNA3.1(-)_fl nm23-M2_GFP (Lane 4). RT-PCR of nm23-M2 presented in panel 
(A) (i) showed the increased expression of nm23-M2 mRNA in MN9D cells 
transfected with pcDNA3.1(-)_fl nm23-M2_GFP (Lane 4). 
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Figure 3.18 A) RT-PCR. Gel photos showing reverse transcription of individual
genes for (i) nm23-M2, (ii) cyclin D1 and (iii) β-actin by RT-PCR.  
 B) Western immunoblot analysis. Protein levels of cyclin D1 and β-
tubulin (loading control) to investigate its relative expression in
transfected MN9D cells.  
 Lane: 1) MN9D with mock transfection, 2) MN9D treated with n-
butyric acid (1mM), 3) MN9D transfected with null GFP plasmid as
control, 4) MN9D transfected with pcDNA3.1(-)_fl nm23-M2_GFP . 
Chapter 3: Results 
 
 78
3.3 SiRNA interference studies of nm23-M2 in MN9D cells 
3.3.1 Knockdown expression of nm23-M2 mRNA upon siRNA 
 interference 
The knockdown effect of nm23-M2 was investigated by using RT-PCR. After 
MN9D cells were transfected with mock siRNA as control and nm23-M2 siRNA 
individually for 24hr, the cells were subjected to total RNA isolation. The total RNA 
isolated were then used for templates for RT-PCR. Specific sets of primers were used 
to generate the inserts of nm23-M2 and β-actin. The PCR products were analyzed 
using DNA agarose gel electrophoresis and the gel photographs taken are shown in 
figure 3.19. From the figure, the RT-PCR of nm23-M2 showed that there was a 
knockdown expression of nm23-M2 mRNA in the sample where nm23-M2 siRNA 
was added to the cells (Lane 2) as compared to the sample where the mock siRNA 
was added (Lane 1). This confirmed that the nm23-M2 siRNA worked well and 
indeed had a transient knockdown effect on the nm23-M2 mRNA level. However, 
further experiment such as real-time PCR can be perform as RT-PCR may not be 
sensitive to show the quantitative differences. 
RT-PCR 
Lane:  








Figure 3.19 RT-PCR of nm23-M2 after siRNA interference. Gel photos
showing reverse transcription of individual genes for (i)
nm23-M2 and (ii) β-actin by RT-PCR. Lane 1) MN9D
transfected with a mock control siRNA for 24hr, 2) MN9D
transfected with nm23-m2 siRNA for 24hr. 
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3.3.2 Morphological appearance of MN9D cells after transient 
siRNA knockdown of nm23-M2 
 All MN9D cells plated in 6-well plates were first treated with 1mM of n-
butyric acid except the control cells, to allow the cells to undergo cell differentiation. 
After adding control siRNA and nm23-M2 siRNA in separate wells for 24hr 
incubation, the morphological appearance of these MN9D cells were examined by 
counting the number of cells bearing neurites using photographs taken from a phase 
contrast inverted microscope.  The consolidated data collected were analyzed and 
plotted into a bar chart as shown in figure 3.20.  
 Majority of the MN9D cells that were treated with 1mM n-butyric acid 
generally exhibited neurite extension as shown in figure 3.6 as mentioned previously 
in the time-course MN9D differentiation experiment. No significant changes were 
observed for cells that were added with control siRNA as majority of the cells still 
displayed neurite outgrowth. This implied that the control siRNA did not have any 
considerable effect on the differentiated MN9D cells. For MN9D cells that were 
added with siRNA specific to nm23-M2, there was a significant decrease in the 
number of cells bearing neurites even though there was 1mM n-butyric acid present 
in the cell medium. 

























































Figure 3.20 A graph showing the morphological changes of MN9D cells after
24hr post-transfection of control siRNA and nm23-M2 siRNA.
MN9D cells transfected with nm23-M2 siRNA had significantly
lesser cells with neurites than cells that were transfected with the
control siRNA as determined by one-way ANOVA test using SPSS
statistical software. *P<0.05.  
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3.3.3 Cell cycle analysis of n-butyric acid-treated MN9D cells when 
nm23-M2 siRNA was added 
Flow cytometry analysis by FACS were also performed to examine the cell 
cycle stages of n-butyric acid treated MN9D cells when added with control siRNA 
and nm23-M2 specific siRNA after 48hr of incubation. There were no significant 
changes in the cell cycle stages of the cells after 24hr, therefore 48hr of incubation 
was chosen. The FACS data were analyzed and plotted as a graph shown below in 
figure 3.21. Interestingly, MN9D cells that were transfected with nm23-M2 siRNA 
did not have any significant change in cell cycle stages as compared to those 
transfected with control siRNA.  
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Figure 3.21 A graph showing the percentage of MN9D cells after 48hr post-
transfection of control and nm23-M2 siRNA. MN9D cells treated with
1mM n-butyric acid had significantly more cells at G1 phase than MN9D
control cells as determined by one-way ANOVA using SPSS software.
*P<0.05. NaB: 1mM n-butyric acid, CS: control siRNA, S1: nm23-M2
siRNA 
*
Chapter 3: Results 
 
 82
3.3.4 SNAP-25 protein level of n-butyric acid-treated MN9D cells 
did not increase when nm23-M2 siRNA was added  
 The phenotypic marker of maturation, SNAP-25 were also examined in 
MN9D cells treated with n-butyric acid and nm23-M2 siRNA. The western 
immunoblot analysis of SNAP-25 is shown in figure 3.22. Both samples of MN9D 
cells treated with n-butyric acid (Lane 2) and with the addition of control siRNA 
(Lane 3) showed up-regulation of protein levels of SNAP-25. MN9D cells treated 
with n-butyric acid plus nm23-M2-specific siRNA (Lane 4) displayed the same 
protein level as the control MN9D cells (Lane 1) as the level of SNAP-25 did not 














Figure 3.22 Western immunoblots showing siRNA interference results after 24hr of
transfection using mouse anti-SNAP-25 monoclonal antibody and mouse
anti-β-tubulin monoclonal antibody as loading control. Lane 1) MN9D
control, 2) MN9D treated with n-butyric acid, 3) MN9D treated with n-
butyric acid and mock siRNA, 4) MN9D treated with n-butyric acid and
Nm23-m2 siRNA. The blot was from one experiment representative of
three similar repeats. 
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3.3.5 Cyclin D1 protein level of n-butyric acid-treated MN9D cells 
did not decrease when nm23-M2 siRNA was added 
The protein expression of the key cell cycle regulatory gene, cyclin D1, was 
also investigated after transient siRNA knockdown of nm23-M2. The western 
immunoblot analysis of cyclin D1 is shown in figure 3.23. As mentioned in the 
overexpression studies in section 3.2.4, the protein levels of cyclin D1 were down-
regulated in differentiated cells. Both samples of MN9D cells treated with n-butyric 
acid (Lane 2) and with the addition of control siRNA (Lane 3) showed down-
regulation of protein levels of cyclin D1. Whereas in those MN9D cells treated with 
n-butyric acid and with the addition of nm23-M2-specific siRNA, displayed the same 
protein level as the control MN9D cells as the level of cyclin D1 did not decrease 
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Figure 3.23 Western immunoblots showing siRNA interference results after 24hr of
transfection using mouse anti-Cyclin D1 monoclonal antibody and mouse
anti-β-tubulin monoclonal antibody as loading control. Lane 1) MN9D
control, 2) MN9D treated with n-butyric acid, 3) MN9D treated with n-
butyric acid and mock siRNA, 4) MN9D treated with n-butyric acid and
Nm23-m2 siRNA. The blot was from one experiment representative of
three similar repeats. 
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Chapter 4: Discussion 
 
4.1 Choice of cell line model  
The use of a mouse cell line model to elucidate the role of nm23-M2 
represents a powerful means to analyze individual gene expression changes affected 
by various manipulations in a closely controlled environment. The choice of a mouse 
mesencephalic MN9D cell line was most appropriate since both the mouse and 
human species have a high sequence homology in their genetic makeup and gene 
organization, in addition to the possibility of performing in vivo experiments on 
mouse animal model in future investigation. This mesencephalic derived cell line has 
the advantage of representing homogeneous cell population and can be readily 
manipulated, therefore it is used in this study as a valuable tool to address the role of 
nm23-M2 in dopaminergic neuronal differentiation.  
 
4.2 Temporal and spatial expression of nm23-M2 gene 
 Since it is known that nm23/NDPK has several different functions in the cell, 
knowing the expression patterns of nm23-M2 could reveal some clues on its function 
and imply the specific role in cells of different characteristics and origin, hence the 
temporal and spatial expressions of nm23-M2 gene in dopaminergic cell lines were 
investigated in the present study.  
 The temporal expression was studied during n-butyric acid induced MN9D 
differentiation by measuring the endogenous level of nm23-M2 mRNA by semi-
quantitative real-time PCR. It was shown that the endogenous level of nm23-M2 
mRNA in MN9D cells was the highest at the 6th day upon addition of 1mM n-butyric 
acid. From the morphological changes that took place during the 1st to 7th days of 
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differentiation, the first indication of differentiation in MN9D cells was the change of 
its morphology by the flattened cell body appearance, followed by the outgrowth of 
neurites, which eventually leads to the neurite extension which usually takes place on 
the 6th to 7th day. This indicated that nm23-M2 might be involved in the later stages of 
the differentiation pathway where most of the downstream maturation genes 
involving neuritogenesis, synaptogenesis, etc, will be activated. Several previously 
published papers implied a possible connection between nm23 proteins and 
cytoskeleton structures such as intermediate filaments and microtubular network 
(Lombardi et al. 1995; Biggs et al. 1990; Pinon et al. 1999; Roymans et al. 2000), and 
such neuritogenesis events bring about dynamic changes in the cytoskeleton 
structures. These findings might indicate a direct involvement of nm23 in pathways 
regulating cell shape and/or motility. 
 The decision to analyze the localization of nm23-M2 using green fluorescent 
protein techniques was based on the fact that several problems were met during the 
pursuit of this work, such as lack of good commercially available nm23-M2 
antibodies and weak immunoreactivity of the commercially available nm23-M2 
antibodies in MN9D cells. Additionally, GFP-based methods are very sensitive and 
enable us to track fusion proteins in living cells. The spatial expression of the GFP-
tagged nm23-M2 proteins and the subcellular localization experiment using c-MYC-
tagged nm23-M2 proteins revealed that nm23-M2 principally localized in the 
cytoplasm of both MN9D and SH-SY5Y cell lines, despite the difference in the cell 
lineage. GFP-nm23-M2 staining was observed in the form of granum-like structures 
together with the abundantly present diffuse cytosolic staining as shown in figure 
3.13. This observation bears much similarity with a recent report (Bosnar et al. 2004) 
on human nm23-GFP staining in the form of granum-like structure in the cytoplasm 
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of HEp-2 (squamous cell carcinoma of the larynx). Confocal microscopy 
observations by the authors confirmed that the granum-like particles are full structure 
(not hollow) bearing a roughly spherical, but not necessarily symmetrical, shape. 
Considering that a) the granum-like structures never appear in cells transfected with 
the “empty” pcDNA3.1-GFP construct, b) in the cells where they appear, the number 
of the granum-like structures varies from one to several (rarely they can be seen in 
abundance); they are of different size and distribution but often seen adjacent to the 
nucleus, the authors have speculated that the granum-like structures could possibly be 
a consequence of the hetero-multimerization of subunits, leading to a catalytically 
active heterohexamer.  
  
4.3 The role of nm23-M2 in dopaminergic MN9D differentiation 
 The up-regulation of nm23-M2 during dopaminergic MN9D differentiation in 
our previous suppressive subtractive hybridization and micro-array studies 
(manuscript in preparation) led us to speculate that nm23-M2 may play some specific 
roles in dopaminergic neuronal cells and to investigate the role of nm23-M2/NDPKβ 
in neuronal differentiation of MN9D cells. To our surprise, when nm23-M2 was 
overexpressed in MN9D cells, the cells became capable of extending neurites without 
any differentiation inducers. Furthermore, overexpression of nm23-M2 leads to the 
increased protein expression in a maturation marker, SNAP-25. SNAP-25 is a 
presynaptic nerve terminal protein, which is essential for the process of neurite 
outgrowth in vivo and in vitro (Oyler et al. 1989; De Camilli, 1993; Osen-Sand et al. 
1993). Because its expression and subcellular distribution is highly correlated with 
the transformation of growth cones to synaptic terminals, SNAP-25 has been used as 
a marker for synaptogenesis (Catsicas et al. 1991). Previous studies also reported that 
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morphological differentiation was usually accompanied by the increased in SNAP-25 
expression (Oh et al. 1996; Choi et al. 2001; Greenlee et al. 2001). In nerve terminals, 
SNAP-25 participates in docking and/or fusion of synaptic vesicles with the 
plasmalemma, a process essential for synaptic vesicle exocytosis (Hodel, 1998; 
Sorensen, 2005). Decreased SNAP-25 protein levels in the brain of Down syndrome 
and Alzheimer’s disease patients may reflect impaired synaptogenesis or represent 
neuronal loss (Greber et al. 1999). 
 Lakin et al. (1995) reported that the increased expression of Brn-3a POU (Pit-
Oct-Unc) family transcription factor occurs upon differentiation of ND7 cells (rat 
dorsal root ganglion neurons fused with C1300 mouse neuroblastoma cell line) by 
serum removal. The authors have also showed that Brn-3a can activate the SNAP-25 
gene promoter, and the up-regulation of this factor in ND7 cell differentiation may 
therefore be responsible for the corresponding increase in SNAP-25 expression 
during this process. Similarly, the inhibition of Brn-3a expression using an antisense 
approach results in the observed decrease in SNAP-25 expression and hence the 
failure of neurite outgrowth. These results therefore implicate that Brn-3a regulates 
neurite outgrowth acting via the modulation of SNAP-25 gene expression. This 
present study bears certain similarities in the experimental approach to what Lakin et 
al. (1995) has reported. Indeed, overexpression of nm23-M2 induced an increased 
expression of SNAP-25 without any differentiation inducer.  
 SiRNA interference approach instead of antisense approach was used to 
reduce the exogenous expression of nm23-M2 in MN9D cells and SNAP-25 
expression was not increased even though the cells were treated with the 
differentiation inducer, n-butyric acid, hence the low number of cells exhibiting 
neurite outgrowth. Therefore, it is plausible that nm23-M2 gene regulates neurite 
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outgrowth in dopaminergic MN9D cells acting via the modulation of SNAP-25 gene 
expression. However, whether up-regulation of SNAP-25 protein in MN9D/nm23-M2 
directly results in neurite extension or is secondary to other signal transduction 
pathways triggered by nm23-M2 is not known at present. 
  
4.4 The role of nm23-M2 in inducing cell cycle arrest 
Cell cycle withdrawal or growth arrest is mandatory for differentiation in 
many cell types, and genes that regulate the transition from the G1 to the S-phase of 
the cell cycle are involved in such a phenomenon. Cyclin D1 encodes the regulatory 
subunit of a holoenzyme that accelerates cell transit through the G1 phase by forming 
complexes with Cdk4 and Cdk6 (Figure 4.1), which phosphorylate the retinoblastoma 
(Rb) protein (Sherr, 1995), blocking the function of Rb as a repressor of genes 
required for cell proliferation (Chen et al. 1995; Beijersbergen and Bernards, 1996). 
The factors that determine whether cells continue to proliferate or arrest growth and 
differentiate operate during the G1 phase of the cell cycle (Sherr, 1994; Weinberg, 
1995; Bartek et al. 1996).  









Previous studies by other investigators have shown that overexpression of 
nm23 genes could lead to cell cycle arrest in some cell types, such as PC12 cells 
(Lombardi et al. 2001), colon carcinoma cells (Hsu et al. 1994) and human breast 
carcinoma cells  (Howlett et al. 1994). In this study, the FACS results indicated that 
MN9D cells which were overexpressed with nm23-M2 underwent cell cycle arrest 
and have a significant increase in the number of cells in G1 stage, which is also 
reflected by their slow doubling time. The cell cycle marker, cyclin D1 expression 
was also investigated upon overexpression of nm23-M2 in MN9D cells and the 
results showed that cyclin D1 expression both in transcriptional and translational 
levels was significantly decreased. The observation of the increase in number of cells 
in G1 stage and decreased expression of cyclin D1 were also consistent as reflected in 
Figure 4.1 A schematic representation of cell cycle progression showing cyclins
function as regulators of CDK kinases. This cyclin forms a complex with and
functions as a regulatory subunit of CDK4 or CDK6, whose activity is required
for cell cycle G1/S transition.  
Source: http://www.mie.utoronto.ca/labs/lcdlab/biopic/biofigures.htm 
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MN9D cells treated with the differentiating agent, n-butyric acid. Therefore, it is 
possible that nm23-M2 activates transcription of negative regulators (such as Rb) of 
cell cycle and represses transcription of positive regulators (such as cyclin D1, 










Figure 4.2 A schematic representation showing positive and negative
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SiRNA interference of nm23-M2 also has an effect on the expression of cyclin 
D1 in MN9D cells under differentiation condition (addition of 1mM n-butyric acid). 
Upon addition of nm23-M2 siRNA, the protein level of cyclin D1 was not decreased 
in MN9D cells even though they were subjected to the differentiating effect of n-
butyric acid. However, the FACS results showed otherwise, as the G1 phase cell cycle 
arrest in nm23-M2 siRNA-treated MN9D cells under differentiation condition was 
not reversed. This unexpected result led us to speculate that perhaps the knockdown 
effect of nm23-M2 siRNA was transient and short-lived hence the cells were able to 
recover the endogenous level of nm23-M2 after 48 hours. Another possible reason 
that nm23-M2 siRNA approach was not able to overcome n-butyric acid-mediated 
block at G1 phase of cell cycle arrest may be due to the fact that many regulatory 
genes such as Rb, Cdk4/Cdk6, etc (Figure 4.2), that are involved in controlling the 
machinery of G1 to S phase cell cycle transition, thus by reducing the endogenous 
expression of nm23-M2 may not be sufficient enough to prevent cell cycle arrest 
induced by n-butyric acid in MN9D cells. Nonetheless, more experiments are needed 
to be devised in order to elucidate the role of nm23-M2 in modulating the regulatory 
genes controlling the cell cycle progression. It is worth exploring the link between 
nm23-M2 and the cell cycle machinery. 
 
4.5 Further studies to elucidate the differentiation pathway 
 Many studies in the past have tried to gain insight of the differentiation 
pathway underlying the role of the nm23 protein but until now, it is still not known 
which signaling pathway(s) is involved in nm23-mediated neurite extension. Recent 
studies have indicated that activation of stress-activated protein kinases such as c-Jun 
N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) has been 
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implicated in a broad range of biological activities including neuronal differentiation 
(Yao et al. 1997; Iwasaki et al. 1999; Coffey et al. 2000; Takeda et al. 2000; Waetzig 
and Herdegen, 2003). In a previous study by Choi et al. (2001), it was demonstrated 
that phosphorylation of p38 is directly involved in neurite extension of MN9D 
dopaminergic neuronal cells overexpressing calbindin-D28K. Results from Eom et al. 
(2004) indicate that the JNK signal activated by Bcl-2 may play an important role in 
the morphological and in certain aspects of biochemical differentiation of MN9D 
dopaminergic neuronal cells. Hence, it is possible to devise experiments (such as 
treating MN9D/nm23-M2 with a specific JNK inhibitor, SP600125, or a p38 
inhibitor, PD169316), to investigate whether nm23-M2 gene activate the JNK and 
MAPK pathway in the differentiation of dopaminergic neuronal cells. 
Further studies are also needed to elucidate certain critical questions. These 
questions include (i) whether nm23-M2 induces neurite outgrowth in a specific 
population of neuronal cells considering its ubiquitous distribution in many of the cell 
types in vivo; (ii) whether neurite outgrowth in MN9D cells mediated by nm23-M2 is 
dependent on its known phosphotransferase activity; (iii) which specific neuronal 
differentiation pathway is activated by nm23-M2; (iv) what target protein(s) 
downstream in the neuronal pathway act as final effector(s) of neurite elongation. 
Answers to these and other critical questions may enlighten our understanding of the 
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4.6 Future experiments  
 Since proteins that are found in the same complex or in the same location are 
likely to be involved in the same or related cellular process, a useful approach to 
unravel the function of a protein is to identify other interacting proteins, possibly of 
known functions. Likewise, protein chemistry or genetic methods can reveal protein-
protein interaction of nm23-M2/NDPKβ. Due to the hexameric structures of 
eukaryotic NDPKs, they can form homo- or hetero-hexamers with different ratios of 
the subunits (Gilles et al. 1991; Urano et al. 1992). It may be postulated that the 
affinity of the interaction between subunits is higher than any other interaction with 
other different proteins. On the other side, the interactions of nm23 with other 
proteins might require the assembly of the hexameric structure, hence the studies of 
protein-protein interaction of nm23/NDPK were much hindered. Many attempts have 
been made by other investigators to discover novel nm23 protein-protein interactions 
using yeast two-hybrid system, the members of the ROR/RZR nuclear orphan 
receptor subfamily interact with nm23 protein (Paravicini et al. 1996). More 
precisely, rat RZRβ and human RORα were found to strongly interact with nm23-M2 
and they suggested putative synergistic effects of ROR/RZR and nm23-H2 on the N-
myc gene transcription. N-myc gene is essential for normal neurogenesis, regulating 
neural progenitor cell proliferation, differentiation, and nuclear size. Its effects on 
proliferation and differentiation appear due, at least in part, to down-regulation of a 
specific subset of cyclin-dependent kinase inhibitors (Knoepfler et al. 2002). The 
heterogeneity of the interactions so far identified further indicates that nm23 proteins 
cannot be merely regarded as NDPKs, but are multifunctional, hence it will be 
noteworthy to investigate whether the interactions require the hexameric structure, 
Chapter 4: Discussion 
 
 95
known to be essential for the catalytic activity (Lascu et al. 1992), or are otherwise 
mediated by monomeric or dimeric forms of the nm23 proteins. 
This present study has made use of an in vitro MN9D cell model to give a 
better understanding to the role of nm23-M2 in dopaminergic neuronal 
differentiation. The current findings will provide a stepping-stone to transfer the 
experimental procedures into primary culture of mouse midbrain mesencephalic 
progenitor neurons to see whether overexpression of nm23-M2 have any effect on 
neuronal differentiation of the primary cell culture into dopaminergic neurons. The 
dopaminergic neurons could then be subsequently transplanted into animal models for 
further in vivo studies such as behavioural rescue of MPP+ or 6-OHDA lesion animal 
model (O’Malley et al. 2003). If this is promising, these dopaminergic neurons could 
be put into good use in cell replacement therapy for future treatment of 
neurodegenerative brain disorders. 
 
4.7 Conclusion 
 Several biochemical functions have been proposed for the nm23 genes in 
many studies, among which the NDPK activity is the most documented. However, it 
appears that such unspecific enzymatic activity does not solely account for the 
biological effects observed in differentiation process. In this regard, this present study 
is novel in two ways. Firstly, it was demonstrated for the first time that 
overexpression of nm23-M2 itself in MN9D dopaminergic neuronal cells leads to 
robust neuritic outgrowth as typified by the increase in the number of cells bearing 
neurites, increased expression in synaptogenesis marker, SNAP-25 and inducing cell 
cycle arrest as illustrated in the increase in proportion of cells in G1 stage of the cell 
cycle and the decreased expression in a G1-phase cell cycle key regulatory gene, 
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cyclin D1. Secondly, treatment with nm23-M2 siRNA largely abolishes neurite 
outgrowth mediated by differentiation inducing agent, n-butyric acid in MN9D cells, 
implying that nm23-M2 is one of the major contributors to the neurite outgrowth in 
MN9D cells induced by n-butyric acid. Whatever the case, it is clear that up-
regulation of nm23-M2 gene in dopaminergic MN9D cell model promotes neuronal 
differentiation through initiating neurite outgrowth and inducing growth arrest. 
 In conclusion, the present study and the proposed future work aim to elucidate 
the multifunctional role of nm23-M2, particularly in dopaminergic neuronal 
differentiation. These findings may eventually contribute to the understanding of 
pathways or mechanisms on the induction of dopaminergic neuron differentiation that 
could facilitate the development of gene delivery or cell replacement therapeutics for 
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